IL105325A
(en)
*
|
1992-04-16 |
1996-11-14 |
Minnesota Mining & Mfg |
Immunogen/vaccine adjuvant composition
|
US6498147B2
(en)
*
|
1992-05-22 |
2002-12-24 |
The Scripps Research Institute |
Suppression of nuclear factor-κb dependent processes using oligonucleotides
|
CA2110946A1
(en)
*
|
1992-12-09 |
1994-06-10 |
Elazar Rabbani |
Induction of immunocompatibility by nucleic acid
|
US20030109469A1
(en)
*
|
1993-08-26 |
2003-06-12 |
Carson Dennis A. |
Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
|
US5849719A
(en)
*
|
1993-08-26 |
1998-12-15 |
The Regents Of The University Of California |
Method for treating allergic lung disease
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US7935675B1
(en)
|
1994-07-15 |
2011-05-03 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6429199B1
(en)
|
1994-07-15 |
2002-08-06 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules for activating dendritic cells
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6239116B1
(en)
*
|
1994-07-15 |
2001-05-29 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
US6825174B2
(en)
*
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
US5981501A
(en)
*
|
1995-06-07 |
1999-11-09 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating plasmids in lipid bilayers
|
US7034007B1
(en)
*
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
US7422902B1
(en)
*
|
1995-06-07 |
2008-09-09 |
The University Of British Columbia |
Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
|
ATE355375T1
(de)
|
1996-01-04 |
2006-03-15 |
Novartis Vaccines & Diagnostic |
Bakterioferritin aus helicobacter pylori
|
ATE437943T1
(de)
*
|
1996-01-30 |
2009-08-15 |
Univ California |
Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
|
US20030078223A1
(en)
*
|
1996-01-30 |
2003-04-24 |
Eyal Raz |
Compositions and methods for modulating an immune response
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20050119470A1
(en)
*
|
1996-06-06 |
2005-06-02 |
Muthiah Manoharan |
Conjugated oligomeric compounds and their use in gene modulation
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
ES2241042T3
(es)
|
1996-10-11 |
2005-10-16 |
The Regents Of The University Of California |
Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
|
ES2290969T3
(es)
|
1996-10-25 |
2008-02-16 |
Minnesota Mining And Manufacturing Company |
Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
|
EP0855184A1
(de)
*
|
1997-01-23 |
1998-07-29 |
Grayson B. Dr. Lipford |
Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
|
US6884435B1
(en)
*
|
1997-01-30 |
2005-04-26 |
Chiron Corporation |
Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|
AU747577B2
(en)
*
|
1997-01-30 |
2002-05-16 |
Novartis Vaccines And Diagnostics, Inc. |
Use of microparticles with adsorbed antigen to stimulate immune responses
|
US6214806B1
(en)
*
|
1997-02-28 |
2001-04-10 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CPC dinucleotide in the treatment of LPS-associated disorders
|
US6406705B1
(en)
*
|
1997-03-10 |
2002-06-18 |
University Of Iowa Research Foundation |
Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
|
WO1998040100A1
(en)
*
|
1997-03-10 |
1998-09-17 |
Ottawa Civic Loeb Research Institute |
USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
|
US6426334B1
(en)
|
1997-04-30 |
2002-07-30 |
Hybridon, Inc. |
Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
|
US20030104044A1
(en)
*
|
1997-05-14 |
2003-06-05 |
Semple Sean C. |
Compositions for stimulating cytokine secretion and inducing an immune response
|
CA2289702C
(en)
|
1997-05-14 |
2008-02-19 |
Inex Pharmaceuticals Corp. |
High efficiency encapsulation of charged therapeutic agents in lipid vesicles
|
AU7690898A
(en)
|
1997-05-20 |
1998-12-11 |
Ottawa Civic Hospital Loeb Research Institute |
Vectors and methods for immunization or therapeutic protocols
|
EP1003850B1
(de)
|
1997-06-06 |
2009-05-27 |
The Regents of the University of California |
Inhibitoren von immunstimulatorischen dna sequenz aktivität
|
EP1374894A3
(de)
*
|
1997-06-06 |
2004-09-22 |
Dynavax Technologies Corporation |
Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
|
US6589940B1
(en)
|
1997-06-06 |
2003-07-08 |
Dynavax Technologies Corporation |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
US20040006034A1
(en)
*
|
1998-06-05 |
2004-01-08 |
Eyal Raz |
Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
|
EP1009440B1
(de)
*
|
1997-07-03 |
2008-09-17 |
MacFarlane, Donald E. |
Methode zur hemmung immunstimulatorischer mit dna assoziierter antworten
|
AU2003203948B2
(en)
*
|
1997-09-05 |
2005-12-22 |
The Regents Of The University Of California |
Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
|
AU757175B2
(en)
*
|
1997-09-05 |
2003-02-06 |
Regents Of The University Of California, The |
Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
|
AU760549B2
(en)
*
|
1998-04-03 |
2003-05-15 |
University Of Iowa Research Foundation, The |
Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
|
AU3884199A
(en)
*
|
1998-05-06 |
1999-11-23 |
Ottawa Health Research Institute |
Methods for the prevention and treatment of parasitic infections and related diseases using cpg oligonucleotides
|
IL139646A0
(en)
*
|
1998-05-14 |
2002-02-10 |
Coley Pharm Group Inc |
Methods for regulating hematopoiesis using cpg-oligonucleotides
|
CN1307473A
(zh)
|
1998-05-19 |
2001-08-08 |
研究发展基金会 |
三萜组合物和它们的使用方法
|
SI1077722T1
(sl)
|
1998-05-22 |
2007-02-28 |
Ottawa Health Research Inst |
Metode in produkti za induciranje sluznicne imunosti
|
KR19990086271A
(ko)
*
|
1998-05-27 |
1999-12-15 |
손경식 |
면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
|
US6562798B1
(en)
|
1998-06-05 |
2003-05-13 |
Dynavax Technologies Corp. |
Immunostimulatory oligonucleotides with modified bases and methods of use thereof
|
US20030022854A1
(en)
|
1998-06-25 |
2003-01-30 |
Dow Steven W. |
Vaccines using nucleic acid-lipid complexes
|
US20040247662A1
(en)
*
|
1998-06-25 |
2004-12-09 |
Dow Steven W. |
Systemic immune activation method using nucleic acid-lipid complexes
|
US6693086B1
(en)
*
|
1998-06-25 |
2004-02-17 |
National Jewish Medical And Research Center |
Systemic immune activation method using nucleic acid-lipid complexes
|
JP2002521489A
(ja)
*
|
1998-07-27 |
2002-07-16 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
CpGオリゴヌクレオチドの立体異性体および関連する方法
|
PT1104306E
(pt)
|
1998-08-10 |
2006-05-31 |
Antigenics Inc |
Composicoes de cpg e adjuvantes de saponina e seus metodos
|
WO2000016804A1
(en)
*
|
1998-09-18 |
2000-03-30 |
Dynavax Technologies Corporation |
METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
|
WO2000021556A1
(en)
*
|
1998-10-09 |
2000-04-20 |
Dynavax Technologies Corporation |
Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
|
US6867289B1
(en)
*
|
1998-10-26 |
2005-03-15 |
Board Of Regents, The University Of Texas Systems |
Thio-modified aptamer synthetic methods and compositions
|
AU770464B2
(en)
*
|
1998-12-22 |
2004-02-19 |
Seer Pharmaceuticals, Llc |
Treatment of skin lesions
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
CA2362204C
(en)
*
|
1999-02-17 |
2011-11-08 |
John Cooper Cox |
Immunogenic complexes and methods relating thereto
|
PT1154790E
(pt)
*
|
1999-02-26 |
2005-03-31 |
Chiron Srl |
Reforco da actividade bactericida de antigenios contra a neisseria com oligonucleotidos contendo motivos cg
|
CA2689696C
(en)
|
1999-02-26 |
2013-08-06 |
Novartis Vaccines And Diagnostics, Inc. |
Microemulsions with adsorbed macromolecules and microparticles
|
GB2348132B
(en)
*
|
1999-03-02 |
2004-08-04 |
Nedaa Abdul-Ghani Nasif |
Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils
|
FR2790955B1
(fr)
|
1999-03-19 |
2003-01-17 |
Assist Publ Hopitaux De Paris |
Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
|
AU4343700A
(en)
*
|
1999-04-12 |
2000-11-14 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
Oligodeoxynucleotide and its use to induce an immune response
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
WO2000062803A2
(en)
*
|
1999-04-15 |
2000-10-26 |
Board Of Regents, The University Of Texas System |
ppGpp AND pppGpp AS IMMUNOMODULATORY AGENTS
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
BRPI0010612B8
(pt)
|
1999-04-19 |
2021-05-25 |
Smithkline Beecham Biologicals S A |
vacinas
|
GB9908885D0
(en)
*
|
1999-04-19 |
1999-06-16 |
Smithkline Beecham Biolog |
Vccine
|
CA2370708A1
(en)
*
|
1999-04-20 |
2000-10-26 |
Smithkline Beecham Biologicals S.A. |
Vaccine comprising rsv antigen and cpg oligonucleotide
|
ES2250151T3
(es)
*
|
1999-06-29 |
2006-04-16 |
Glaxosmithkline Biologicals S.A. |
Uso de cpg como adyuvante de vacuna contra vih.
|
US20050002958A1
(en)
*
|
1999-06-29 |
2005-01-06 |
Smithkline Beecham Biologicals Sa |
Vaccines
|
US6514948B1
(en)
|
1999-07-02 |
2003-02-04 |
The Regents Of The University Of California |
Method for enhancing an immune response
|
FR2795963A1
(fr)
*
|
1999-07-08 |
2001-01-12 |
Pasteur Merieux Serums Vacc |
Polynucleotide immunostimulant
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
US20050226890A1
(en)
*
|
1999-08-12 |
2005-10-13 |
Cohen David I |
Tat-based vaccine compositions and methods of making and using same
|
CA2784789A1
(en)
*
|
1999-08-13 |
2001-02-22 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
|
DE60041335D1
(de)
|
1999-08-19 |
2009-02-26 |
Dynavax Tech Corp |
Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
|
US20050249794A1
(en)
*
|
1999-08-27 |
2005-11-10 |
Semple Sean C |
Compositions for stimulating cytokine secretion and inducing an immune response
|
CN100368020C
(zh)
*
|
1999-08-27 |
2008-02-13 |
不列颠哥伦比亚大学 |
用于刺激细胞因子分泌和诱导免疫应答的组合物
|
CN1454091A
(zh)
*
|
1999-09-25 |
2003-11-05 |
衣阿华大学研究基金会 |
免疫刺激性核酸
|
US6949520B1
(en)
*
|
1999-09-27 |
2005-09-27 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
EP1688147A1
(de)
*
|
1999-09-27 |
2006-08-09 |
Coley Pharmaceutical Group, Inc. |
Verfahren mittels durch Nukleinsäuren induziertes immunstimulatorisches Interferon
|
WO2001022990A2
(en)
*
|
1999-09-27 |
2001-04-05 |
Coley Pharmaceutical Group, Inc. |
Methods related to immunostimulatory nucleic acid-induced interferon
|
ES2564463T3
(es)
|
1999-10-29 |
2016-03-22 |
Glaxosmithkline Biologicals S.A. |
Péptidos antigénicos de Neisseriales
|
US7223398B1
(en)
|
1999-11-15 |
2007-05-29 |
Dynavax Technologies Corporation |
Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
|
EP1322655B1
(de)
*
|
2000-01-14 |
2007-11-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
US20010044416A1
(en)
*
|
2000-01-20 |
2001-11-22 |
Mccluskie Michael J. |
Immunostimulatory nucleic acids for inducing a Th2 immune response
|
US6552006B2
(en)
|
2000-01-31 |
2003-04-22 |
The Regents Of The University Of California |
Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
|
US7585847B2
(en)
*
|
2000-02-03 |
2009-09-08 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for the treatment of asthma and allergy
|
US20030130217A1
(en)
*
|
2000-02-23 |
2003-07-10 |
Eyal Raz |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
AU4175101A
(en)
|
2000-02-23 |
2001-09-03 |
Univ California |
Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
|
WO2001062092A1
(en)
*
|
2000-02-25 |
2001-08-30 |
Thomas Jefferson University |
Formulations and methods for using the same to elicit an immune response
|
US20040131628A1
(en)
*
|
2000-03-08 |
2004-07-08 |
Bratzler Robert L. |
Nucleic acids for the treatment of disorders associated with microorganisms
|
US7157437B2
(en)
|
2000-03-10 |
2007-01-02 |
Dynavax Technologies Corporation |
Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
|
US7129222B2
(en)
*
|
2000-03-10 |
2006-10-31 |
Dynavax Technologies Corporation |
Immunomodulatory formulations and methods for use thereof
|
US20030129251A1
(en)
|
2000-03-10 |
2003-07-10 |
Gary Van Nest |
Biodegradable immunomodulatory formulations and methods for use thereof
|
US20020098199A1
(en)
|
2000-03-10 |
2002-07-25 |
Gary Van Nest |
Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
|
US20010046967A1
(en)
|
2000-03-10 |
2001-11-29 |
Gary Van Nest |
Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
|
AU2001251407A1
(en)
*
|
2000-04-07 |
2001-10-23 |
The Regents Of The University Of California |
Synergistic improvements to polynucleotide vaccines
|
PT1278761E
(pt)
*
|
2000-05-01 |
2005-08-31 |
Hybridon Inc |
Modulacao da estimulacao imunitaria mediada por oligonucleotidos de cpg, por modificacao posicional de nucleosidos
|
US6696064B2
(en)
*
|
2000-06-20 |
2004-02-24 |
The United States Of America As Represented By The Department Of Health And Human Services |
Methods of protecting vasculature from damage by diphtheria toxin-and pseudomonas toxin-based immunotoxins during therapy
|
AU2001276831A1
(en)
|
2000-06-22 |
2002-01-02 |
Rxkinetix, Inc. |
Delivery vehicle composition and methods for delivering antigens and other drugs
|
SI1296714T1
(sl)
|
2000-06-22 |
2010-01-29 |
S For Entpr University Of Iowa |
Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
|
BRPI0111830B8
(pt)
*
|
2000-06-23 |
2021-05-25 |
American Cyanamid Co |
método de produção de partículas semelhantes ao vírus da influenza (vlps), vlps da influenza, vlps quiméricas, composições imunogênica e farmacêutica, e, usos de vlps da influenza e de vlps quiméricas
|
WO2002002172A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Univ Jefferson |
Dna palindrome - oligoguanylic acid compositions and uses thereof
|
KR100917101B1
(ko)
*
|
2000-08-04 |
2009-09-15 |
도요 보세키 가부시키가이샤 |
플렉시블 금속적층체 및 그 제조방법
|
WO2006033665A1
(en)
*
|
2004-03-16 |
2006-03-30 |
Inist Inc. |
Tat-based vaccine compositions and methods of making and using same
|
WO2005090392A1
(en)
*
|
2004-03-16 |
2005-09-29 |
Inist Inc. |
Tat-based tolerogen compositions and methods of making and using same
|
WO2002016549A2
(en)
*
|
2000-08-25 |
2002-02-28 |
Yeda Research And Development Co. Ltd. |
METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
|
JP2005500806A
(ja)
*
|
2000-09-15 |
2005-01-13 |
コーリー ファーマシューティカル ゲーエムベーハー |
CpGに基づく免疫アゴニスト/免疫アンタゴニストの高スループットスクリーニングのためのプロセス
|
ES2298269T3
(es)
*
|
2000-09-26 |
2008-05-16 |
Idera Pharmaceuticals, Inc. |
Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
|
IL154853A0
(en)
|
2000-10-27 |
2003-10-31 |
Chiron Spa |
Nucleic acids and proteins from streptococcus groups a & b
|
CA2598144A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
WO2002069369A2
(en)
|
2000-12-08 |
2002-09-06 |
Coley Pharmaceutical Gmbh |
Cpg-like nucleic acids and methods of use thereof
|
CN1293192C
(zh)
*
|
2000-12-27 |
2007-01-03 |
戴纳瓦克斯技术公司 |
免疫调节性多核苷酸及其使用方法
|
KR20030070101A
(ko)
*
|
2001-01-12 |
2003-08-27 |
아마토 세이야쿠 가부시키가이샤 |
미생물 감염 방지제
|
US7264810B2
(en)
*
|
2001-01-19 |
2007-09-04 |
Cytos Biotechnology Ag |
Molecular antigen array
|
WO2002060476A2
(de)
*
|
2001-01-31 |
2002-08-08 |
Mologen Forschungs-, Entwicklungs- Und Vertriebs Gmbh |
Tumorvakzine
|
US20030050268A1
(en)
*
|
2001-03-29 |
2003-03-13 |
Krieg Arthur M. |
Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
|
US20070128229A1
(en)
*
|
2002-04-12 |
2007-06-07 |
Wyeth |
Surface proteins of Streptococcus pyogenes
|
CA2443493A1
(en)
*
|
2001-04-13 |
2002-10-24 |
Wyeth |
Surface proteins of streptococcus pyogenes
|
EP1572868A4
(de)
|
2001-04-16 |
2007-04-04 |
Wyeth Corp |
Neue, polypeptidantigene codierende offene leseraster aus streptococcus pneumoniae und verwendungen davon
|
US7034140B2
(en)
*
|
2001-04-24 |
2006-04-25 |
E.I. Du Pont De Nemours And Company |
Genes involved in isoprenoid compound production
|
CA2448031A1
(en)
|
2001-05-21 |
2002-11-28 |
Intercell Ag |
Method for stabilising of nucleic acids
|
US6818787B2
(en)
*
|
2001-06-11 |
2004-11-16 |
Xenoport, Inc. |
Prodrugs of GABA analogs, compositions and uses thereof
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
DK2423335T3
(da)
|
2001-06-21 |
2014-08-18 |
Dynavax Tech Corp |
Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
|
NZ530632A
(en)
*
|
2001-06-29 |
2007-04-27 |
Chiron Corp |
HCV E1E2 vaccine compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or CpG oligonucleotides
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US20030148316A1
(en)
*
|
2001-08-01 |
2003-08-07 |
Lipford Grayson B. |
Methods and compositions relating to plasmacytoid dendritic cells
|
WO2003025119A2
(en)
*
|
2001-08-03 |
2003-03-27 |
Medarex, Inc. |
Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
|
AU2002326561B2
(en)
*
|
2001-08-07 |
2008-04-03 |
Dynavax Technologies Corporation |
Immunomodulatory compositions, formulations, and methods for use thereof
|
WO2003020884A2
(en)
*
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
ES2314099T3
(es)
*
|
2001-08-17 |
2009-03-16 |
Coley Pharmaceutical Gmbh |
Oligonucleotidos inmunoestimulantes con motivos combinados con actividad mejorada.
|
WO2003018611A2
(en)
|
2001-08-24 |
2003-03-06 |
University Of Victoria Innovation And Development Corporation |
Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
|
MXPA04001972A
(es)
*
|
2001-08-30 |
2005-02-17 |
3M Innovative Properties Co |
Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune.
|
WO2003022296A1
(en)
*
|
2001-09-07 |
2003-03-20 |
The Trustees Of Boston University |
Method and composition for treating immune complex associated disorders
|
ATE447967T1
(de)
|
2001-09-14 |
2009-11-15 |
Cytos Biotechnology Ag |
Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
|
US20030091593A1
(en)
*
|
2001-09-14 |
2003-05-15 |
Cytos Biotechnology Ag |
In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
|
AU2002353783A1
(en)
|
2001-09-24 |
2003-04-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
US20030119774A1
(en)
*
|
2001-09-25 |
2003-06-26 |
Marianna Foldvari |
Compositions and methods for stimulating an immune response
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
KR20050034583A
(ko)
*
|
2001-10-05 |
2005-04-14 |
콜리 파마슈티칼 게엠베하 |
톨-유사 수용체 3 신호 전달 작용제 및 길항제
|
WO2003030656A2
(en)
|
2001-10-06 |
2003-04-17 |
Merial Limited |
Methods and compositions for promoting growth and innate immunity in young animals
|
KR20050048539A
(ko)
*
|
2001-10-06 |
2005-05-24 |
메리얼엘엘씨 |
CpG 제제 및 관련된 방법
|
MX339524B
(es)
|
2001-10-11 |
2016-05-30 |
Wyeth Corp |
Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
|
EP1478371A4
(de)
*
|
2001-10-12 |
2007-11-07 |
Univ Iowa Res Found |
Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
WO2003039595A2
(en)
*
|
2001-11-07 |
2003-05-15 |
Inex Pharmaceuticals Corporation |
Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
|
EP1441758A2
(de)
*
|
2001-11-09 |
2004-08-04 |
MediGene Aktiengesellschaft |
Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
|
WO2003043572A2
(en)
*
|
2001-11-16 |
2003-05-30 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor pathways
|
US7179798B2
(en)
*
|
2001-11-16 |
2007-02-20 |
Russell R. Roby |
Methods and compositions for the treatment of pain and other hormone-allergy-related symptoms using dilute hormone solutions
|
AU2004220469B2
(en)
*
|
2001-11-29 |
2010-07-29 |
3M Innovative Properties Company |
Methods of improving skin quality
|
WO2003047602A1
(en)
*
|
2001-12-07 |
2003-06-12 |
Intercell Ag |
Immunostimulatory oligodeoxynucleotides
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
EP1467755A1
(de)
*
|
2001-12-21 |
2004-10-20 |
Antigenics Inc. |
Immunreaktive reagentien und saponine enthaltende zusammensetzungen sowie verfahren zur verwendung davon
|
EP1474432A1
(de)
|
2002-02-04 |
2004-11-10 |
Biomira Inc. |
Immunstimulierende, kovalent lipid-modifizierte oligonukleotide
|
US8088388B2
(en)
*
|
2002-02-14 |
2012-01-03 |
United Biomedical, Inc. |
Stabilized synthetic immunogen delivery system
|
JP4646516B2
(ja)
*
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
MXPA04008023A
(es)
*
|
2002-02-22 |
2004-11-26 |
3M Innovative Properties Co |
Metodo para reducir y tratar inmunosupresion inducida por uvb.
|
US6923958B2
(en)
*
|
2002-03-02 |
2005-08-02 |
The Scripps Research Institute |
DNA vaccines encoding CEA and a CD40 ligand and methods of use thereof
|
EP2258712A3
(de)
*
|
2002-03-15 |
2011-05-04 |
Multicell Immunotherapeutics, Inc. |
Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
|
KR100981471B1
(ko)
*
|
2002-03-15 |
2010-09-10 |
더 큐레이터스 오브 더 유니버시티 오브 미주리 |
효소 활성이 감소된 형별불능 헤모필러스 인플루엔자의p4 변형 단백질
|
EP1485403A4
(de)
*
|
2002-03-15 |
2007-08-08 |
Multicell Immunotherapeutics I |
Zusammensetzungen und verfahren zur einleitung bzw. verstärkung von antikörper- und haupthistokompatibilität-klasse-i- oder -klasse-ii-beschränkten t-zell-reaktionen unter anwendung von immunmodulierenden, nicht-codierenden rna-motiven
|
ES2734652T3
(es)
|
2002-04-04 |
2019-12-11 |
Zoetis Belgium S A |
Oligorribonucleótidos inmunoestimulantes que contienen G y U
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
US20040013649A1
(en)
*
|
2002-05-10 |
2004-01-22 |
Inex Pharmaceuticals Corporation |
Cancer vaccines and methods of using the same
|
US20040009944A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Methylated immunostimulatory oligonucleotides and methods of using the same
|
US20040009943A1
(en)
*
|
2002-05-10 |
2004-01-15 |
Inex Pharmaceuticals Corporation |
Pathogen vaccines and methods for using the same
|
US9045727B2
(en)
|
2002-05-17 |
2015-06-02 |
Emory University |
Virus-like particles, methods of preparation, and immunogenic compositions
|
US20060088909A1
(en)
*
|
2002-05-17 |
2006-04-27 |
Compans Richard W |
Virus-like particles, methods of preparation, and immunogenic compositions
|
KR100456681B1
(ko)
*
|
2002-05-22 |
2004-11-10 |
주식회사 대웅 |
박테리아의 염색체 dna 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
|
CA2388049A1
(en)
|
2002-05-30 |
2003-11-30 |
Immunotech S.A. |
Immunostimulatory oligonucleotides and uses thereof
|
WO2003103586A2
(en)
*
|
2002-06-05 |
2003-12-18 |
Coley Pharmaceutical Group, Inc. |
Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
|
BR0311995A
(pt)
*
|
2002-06-20 |
2005-04-05 |
Cytos Biotechnology Ag |
Partìculas semelhantes a vìrus empacotadas para o uso como adjuvantes: método de preparação e uso
|
JP2005532067A
(ja)
*
|
2002-07-03 |
2005-10-27 |
コーリー ファーマシューティカル グループ,インコーポレイテッド |
刺激性免疫応答用の核酸組成物
|
US7807803B2
(en)
*
|
2002-07-03 |
2010-10-05 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7576066B2
(en)
*
|
2002-07-03 |
2009-08-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7605138B2
(en)
*
|
2002-07-03 |
2009-10-20 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US20040053880A1
(en)
*
|
2002-07-03 |
2004-03-18 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
US7569553B2
(en)
*
|
2002-07-03 |
2009-08-04 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid compositions for stimulating immune responses
|
AU2003255969A1
(en)
*
|
2002-07-17 |
2004-02-02 |
Coley Pharmaceutical Gmbh |
Use of cpg nucleic acids in prion-disease
|
US20060270620A1
(en)
*
|
2002-07-23 |
2006-11-30 |
University Of South Florida |
Method of Enhancing Therapeutic Effect of Nucleic Acids
|
WO2004011650A2
(en)
|
2002-07-24 |
2004-02-05 |
Intercell Ag |
Antigens encoded by alternative reading frame from pathogenic viruses
|
EP1575504A4
(de)
|
2002-08-01 |
2009-11-04 |
Us Gov Health & Human Serv |
Verfahren zur behandlung von entzündlichen arthropathien mit suppressoren der cpg-oligonucleotide
|
DE60335010D1
(de)
|
2002-08-15 |
2010-12-30 |
3M Innovative Properties Co |
Immunstimulatorische zusammensetzungen und verfahren zur stimulierung einer immunantwort
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
US7785608B2
(en)
*
|
2002-08-30 |
2010-08-31 |
Wyeth Holdings Corporation |
Immunogenic compositions for the prevention and treatment of meningococcal disease
|
US7595303B1
(en)
*
|
2002-09-05 |
2009-09-29 |
University Of South Florida |
Genetic adjuvants for immunotherapy
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
WO2004024182A2
(en)
|
2002-09-13 |
2004-03-25 |
Intercell Ag |
Method for isolating hepatitis c virus peptides
|
BR0314236A
(pt)
*
|
2002-09-13 |
2005-08-09 |
Replicor Inc |
Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
US7301554B2
(en)
*
|
2002-09-20 |
2007-11-27 |
Ricoh Company, Ltd. |
Light scanning device, scanning line adjusting method, scanning line adjusting control method, image forming apparatus, and image forming method
|
WO2004031382A1
(ja)
*
|
2002-10-02 |
2004-04-15 |
Mochida Pharmaceutical Co., Ltd. |
新規なモノクローナル抗体の作製方法
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
EP2351579B1
(de)
|
2002-10-11 |
2016-09-21 |
Novartis Vaccines and Diagnostics S.r.l. |
Poylpeptidimpfstoffe zum breiten Schutz gegen hypervirulente Meningo-kokken-Linien
|
EP1578459A3
(de)
*
|
2002-10-25 |
2005-11-23 |
University of Connecticut Health Center |
Gerät und verfahren für die immuntherapie von krebs durch kontrollierte zelllyse
|
SI2241325T1
(sl)
|
2002-10-29 |
2012-05-31 |
Coley Pharm Group Inc |
Uporaba CPG oligonukleotidov pri zdravljenju okužbe z virusom hepatitisa C
|
JP4976653B2
(ja)
*
|
2002-11-01 |
2012-07-18 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシス |
免疫刺激性CpGオリゴヌクレオチドを用いてバイオテロ病原体による感染症を予防する方法
|
WO2004044136A2
(en)
*
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
|
EP2279746B1
(de)
|
2002-11-15 |
2013-10-02 |
Novartis Vaccines and Diagnostics S.r.l. |
Oberflächenproteine in neisseria meningitidis
|
US7811813B2
(en)
*
|
2002-11-21 |
2010-10-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and immune modulatory nucleic acid compositions for preventing and treating disease
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US8039443B2
(en)
*
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
AU2003300831A1
(en)
*
|
2002-12-11 |
2004-06-30 |
Hawaii Biotech, Inc. |
Recombinant vaccine against flavivirus infection
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
WO2004053057A2
(en)
*
|
2002-12-11 |
2004-06-24 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
WO2004053104A2
(en)
*
|
2002-12-11 |
2004-06-24 |
Coley Pharmaceutical Group, Inc. |
5’ cpg nucleic acids and methods of use
|
NZ541027A
(en)
|
2002-12-23 |
2008-04-30 |
Dynavax Tech Corp |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
WO2004058159A2
(en)
*
|
2002-12-23 |
2004-07-15 |
Dynavax Technologies Corporation |
Branched immunomodulatory compounds and methods of using the same
|
US8158768B2
(en)
*
|
2002-12-23 |
2012-04-17 |
Dynavax Technologies Corporation |
Immunostimulatory sequence oligonucleotides and methods of using the same
|
EP2263687B1
(de)
|
2002-12-27 |
2015-03-25 |
Novartis Vaccines and Diagnostics, Inc. |
Immunogene zusammensetzungen enthaltend phospholipid
|
JP2006512391A
(ja)
|
2002-12-30 |
2006-04-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
組み合わせ免疫賦活薬
|
ATE552844T1
(de)
|
2003-01-30 |
2012-04-15 |
Novartis Ag |
Injizierbarer impfstoff gegen multiple meningokokken-serogruppen
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
JP2006517974A
(ja)
*
|
2003-02-13 |
2006-08-03 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物およびトル様受容体8に関する方法および組成物
|
JP4976848B2
(ja)
|
2003-02-20 |
2012-07-18 |
ユニバーシティー オブ コネティカット ヘルス センター |
アルファ(2)マクログロブリン−抗原分子複合体を用いる癌および感染性疾患の治療のための方法および組成物
|
GB2398783A
(en)
|
2003-02-26 |
2004-09-01 |
Antonio Lanzavecchia |
A method for producing immortalised human B memory lymphocytes
|
EP1599726A4
(de)
*
|
2003-02-27 |
2009-07-22 |
3M Innovative Properties Co |
Selektive modulation von tlr-vermittelter biologischer aktivität
|
JP2006519866A
(ja)
|
2003-03-04 |
2006-08-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
Uv誘発性の表皮の新形成の予防的治療
|
CN100439386C
(zh)
*
|
2003-03-05 |
2008-12-03 |
长春华普生物技术有限公司 |
增强蛋白类疫苗免疫效果的含CpG单链脱氧寡核苷酸
|
AU2004220465A1
(en)
|
2003-03-13 |
2004-09-23 |
3M Innovative Properties Company |
Method of tattoo removal
|
DE602004029657D1
(de)
|
2003-03-24 |
2010-12-02 |
Intercell Ag |
Verbesserte impfstoffe
|
US20040192585A1
(en)
*
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
NZ542323A
(en)
*
|
2003-03-26 |
2008-07-31 |
Cytos Biotechnology Ag |
Melan-A peptide analogue-virus-like-particle conjugates
|
US7537767B2
(en)
|
2003-03-26 |
2009-05-26 |
Cytis Biotechnology Ag |
Melan-A- carrier conjugates
|
CA2520181A1
(en)
*
|
2003-03-26 |
2004-10-14 |
Astral Inc. |
Selected rna motifs to include cell death and/or apoptosis
|
US20060210588A1
(en)
*
|
2003-03-26 |
2006-09-21 |
Cytos Biotechnology Ag |
Hiv-peptide-carrier-conjugates
|
EP1608403A2
(de)
*
|
2003-04-02 |
2005-12-28 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatorische nukleinsäure öl-in-wasser emulsionen zur topischen anwendung
|
US7923560B2
(en)
*
|
2003-04-10 |
2011-04-12 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
NZ543467A
(en)
|
2003-04-10 |
2008-07-31 |
Novartis Vaccines & Diagnostic |
The severe acute respiratory syndrome coronavirus
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
AU2004232848A1
(en)
|
2003-04-21 |
2004-11-04 |
Archemix Corp. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
JP4673217B2
(ja)
*
|
2003-04-23 |
2011-04-20 |
由紀夫 佐藤 |
メチル化CpGポリヌクレオチド
|
US20050250106A1
(en)
*
|
2003-04-24 |
2005-11-10 |
David Epstein |
Gene knock-down by intracellular expression of aptamers
|
WO2004096136A2
(en)
*
|
2003-04-25 |
2004-11-11 |
Chiron Corporation |
Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof
|
WO2004096144A2
(en)
*
|
2003-04-28 |
2004-11-11 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
WO2004100965A1
(ja)
*
|
2003-05-15 |
2004-11-25 |
Japan Science And Technology Agency |
免疫刺激剤
|
US8080642B2
(en)
|
2003-05-16 |
2011-12-20 |
Vical Incorporated |
Severe acute respiratory syndrome DNA compositions and methods of use
|
ES2596553T3
(es)
|
2003-06-02 |
2017-01-10 |
Glaxosmithkline Biologicals Sa |
Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
|
US7803386B2
(en)
|
2003-06-05 |
2010-09-28 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
|
KR101137572B1
(ko)
*
|
2003-06-11 |
2012-05-30 |
이데라 파마슈티칼즈, 인코포레이티드 |
안정화된 면역조절 올리고뉴클레오티드
|
EP1635846A4
(de)
*
|
2003-06-20 |
2009-01-28 |
Coley Pharm Gmbh |
Kleinmolekülige tlr (toll-like receptor)-antagonisten
|
WO2005004907A1
(en)
*
|
2003-07-10 |
2005-01-20 |
Cytos Biotechnology Ag |
Packaged virus-like particles
|
US20050013812A1
(en)
*
|
2003-07-14 |
2005-01-20 |
Dow Steven W. |
Vaccines using pattern recognition receptor-ligand:lipid complexes
|
CA2534042A1
(en)
*
|
2003-07-31 |
2005-02-10 |
3M Innovative Properties Company |
Compositions for encapsulation and controlled release
|
CN1852711A
(zh)
*
|
2003-08-05 |
2006-10-25 |
3M创新有限公司 |
使用免疫响应调节化合物的传染病预防
|
TW200524927A
(en)
*
|
2003-08-12 |
2005-08-01 |
3M Innovative Properties Co |
Hydroxylamine substituted imidazo-containing compounds
|
US20060035242A1
(en)
|
2004-08-13 |
2006-02-16 |
Michelitsch Melissa D |
Prion-specific peptide reagents
|
US20050065136A1
(en)
*
|
2003-08-13 |
2005-03-24 |
Roby Russell R. |
Methods and compositions for the treatment of infertility using dilute hormone solutions
|
WO2005020902A2
(en)
*
|
2003-08-21 |
2005-03-10 |
Cytokine Pharmasciences, Inc. |
Compositions and methods for treating and diagnosing irritable bowel syndrome
|
EP1658035A4
(de)
*
|
2003-08-25 |
2007-08-22 |
3M Innovative Properties Co |
Abgabe von die immunantwort modifizierenden verbindungen
|
AU2004266162A1
(en)
*
|
2003-08-25 |
2005-03-03 |
3M Innovative Properties Company |
Immunostimulatory combinations and treatments
|
WO2005020999A1
(en)
*
|
2003-08-27 |
2005-03-10 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted imidazoquinolines
|
MXPA06002408A
(es)
*
|
2003-09-02 |
2006-06-20 |
3M Innovative Properties Co |
Metodos relacionados al tratamiento de condiciones asociadas a la mucosa.
|
JP2007504269A
(ja)
*
|
2003-09-05 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
Cd5+b細胞リンパ腫の治療方法
|
EP1670507A4
(de)
|
2003-09-12 |
2007-10-17 |
Antigenics Inc |
Vakzine zur behandlung und prävention von herpes simplex-virusinfektion
|
US7615539B2
(en)
*
|
2003-09-25 |
2009-11-10 |
Coley Pharmaceutical Group, Inc. |
Nucleic acid-lipophilic conjugates
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
BR122017002991B1
(pt)
|
2003-10-02 |
2023-01-10 |
Novartis Vaccines And Diagnostics S.R.L. |
Composições imunogênicas aquosas para múltiplos sorogrupos meningocócicos
|
KR101154101B1
(ko)
*
|
2003-10-03 |
2012-06-11 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
알콕시 치환된 이미다조퀴놀린
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
US7544697B2
(en)
*
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
AU2004280143A1
(en)
*
|
2003-10-11 |
2005-04-21 |
Tekmira Pharmaceuticals Corporation |
Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
|
GB0323965D0
(en)
*
|
2003-10-13 |
2003-11-19 |
Glaxosmithkline Biolog Sa |
Immunogenic compositions
|
US8188254B2
(en)
*
|
2003-10-30 |
2012-05-29 |
Coley Pharmaceutical Gmbh |
C-class oligonucleotide analogs with enhanced immunostimulatory potency
|
CA2543685A1
(en)
*
|
2003-10-31 |
2005-05-12 |
3M Innovative Properties Company |
Neutrophil activation by immune response modifier compounds
|
US20050239733A1
(en)
*
|
2003-10-31 |
2005-10-27 |
Coley Pharmaceutical Gmbh |
Sequence requirements for inhibitory oligonucleotides
|
US20050100983A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Coley Pharmaceutical Gmbh |
Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
|
CN1906192A
(zh)
*
|
2003-11-14 |
2007-01-31 |
3M创新有限公司 |
羟胺取代的咪唑环化合物
|
US7897767B2
(en)
|
2003-11-14 |
2011-03-01 |
3M Innovative Properties Company |
Oxime substituted imidazoquinolines
|
CA2547020C
(en)
*
|
2003-11-25 |
2014-03-25 |
3M Innovative Properties Company |
1h-imidazo[4,5-c]pyridine-4-amine derivatives as immune response modifier
|
US20050277127A1
(en)
*
|
2003-11-26 |
2005-12-15 |
Epitomics, Inc. |
High-throughput method of DNA immunogen preparation and immunization
|
US20050287118A1
(en)
*
|
2003-11-26 |
2005-12-29 |
Epitomics, Inc. |
Bacterial plasmid with immunological adjuvant function and uses thereof
|
JP2007513165A
(ja)
*
|
2003-12-02 |
2007-05-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
Irm化合物を含む併用薬および治療方法
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
US9090673B2
(en)
*
|
2003-12-12 |
2015-07-28 |
City Of Hope |
Synthetic conjugate of CpG DNA and T-help/CTL peptide
|
BRPI0417689A8
(pt)
|
2003-12-17 |
2017-04-25 |
Elan Pharm Inc |
Método para conjugar um imonógeno de peptídeo, composição, conjugado, composição imunogênica, método para induzir uma resposta imune em um indivíduo mamífero, e, uso do conjugado
|
WO2005058940A2
(en)
|
2003-12-17 |
2005-06-30 |
Wyeth |
Immunogenic peptide carrier conjugates and methods of producing same
|
JP4817599B2
(ja)
*
|
2003-12-25 |
2011-11-16 |
独立行政法人科学技術振興機構 |
免疫活性増強剤とこれを用いた免疫活性の増強方法
|
WO2005066170A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
EP1699788A2
(de)
*
|
2003-12-30 |
2006-09-13 |
3M Innovative Properties Company |
Imidazochinolinyl-, imidazopyridinyl- und imidazonaphthyridinylsulfonamide
|
US20050239735A1
(en)
*
|
2003-12-30 |
2005-10-27 |
3M Innovative Properties Company |
Enhancement of immune responses
|
KR100558851B1
(ko)
*
|
2004-01-08 |
2006-03-10 |
학교법인연세대학교 |
면역조절능력이 증가된 CpG 올리고데옥시뉴클레오티드변형체
|
WO2005072290A2
(en)
*
|
2004-01-23 |
2005-08-11 |
Joslin Diabetes Center |
Methods of treating, reducing, or preventing autoimmune conditions
|
US20050181035A1
(en)
*
|
2004-02-17 |
2005-08-18 |
Dow Steven W. |
Systemic immune activation method using non CpG nucleic acids
|
EP2415481A3
(de)
|
2004-02-19 |
2012-04-18 |
Coley Pharmaceutical Group, Inc. |
Immunstimulatorische Virale RNA-Oligonucleotide
|
CN1918293A
(zh)
*
|
2004-02-20 |
2007-02-21 |
莫洛根股份公司 |
用于对人及高等动物进行治疗性和预防性免疫刺激的取代的非编码核酸分子
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
CA2559371C
(en)
|
2004-03-09 |
2014-07-08 |
Chiron Corporation |
Influenza virus vaccines
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US7820175B2
(en)
|
2004-03-19 |
2010-10-26 |
Herbal Spring, Llc |
Herbal therapy for the treatment of food allergy
|
TW200612932A
(en)
*
|
2004-03-24 |
2006-05-01 |
3M Innovative Properties Co |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
TWI235440B
(en)
*
|
2004-03-31 |
2005-07-01 |
Advanced Semiconductor Eng |
Method for making leadless semiconductor package
|
US20060019916A1
(en)
*
|
2004-04-02 |
2006-01-26 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory nucleic acids for inducing IL-10 responses
|
US20050260755A1
(en)
*
|
2004-04-06 |
2005-11-24 |
Isis Pharmaceuticals, Inc. |
Sequential delivery of oligomeric compounds
|
WO2005105106A2
(en)
*
|
2004-04-21 |
2005-11-10 |
Roby Russell R |
Hormone treatment of macular degeneration
|
WO2005105107A2
(en)
*
|
2004-04-21 |
2005-11-10 |
Roby Russell R |
Hormone treatment of multiple sclerosis
|
US7579450B2
(en)
*
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
BRPI0510430A
(pt)
*
|
2004-04-28 |
2007-10-30 |
3M Innovative Properties Co |
composições e métodos para vacinação mucosal
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
WO2005105140A2
(en)
|
2004-04-30 |
2005-11-10 |
Chiron Srl |
Meningococcal conjugate vaccination
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
AU2005247341B2
(en)
*
|
2004-05-06 |
2008-05-08 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
GB0410220D0
(en)
|
2004-05-07 |
2004-06-09 |
Kirkham Lea Ann |
Mutant pneumolysin proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
CN1296378C
(zh)
*
|
2004-05-17 |
2007-01-24 |
中国人民解放军第三军医大学 |
高免疫活性 CpG-S ODN 和拮抗 CpG-S ODN 作用的 CpG-N ODN 的基因序列及其应用
|
CA2566355C
(en)
*
|
2004-05-18 |
2014-04-15 |
Vical Incorporated |
Influenza virus vaccine composition and methods of use
|
MXPA06013448A
(es)
|
2004-05-21 |
2007-01-23 |
Wyeth Corp |
Proteina alterada que liga a la fibronectina en staphylococcus aureus.
|
EP2811027A1
(de)
|
2004-05-21 |
2014-12-10 |
Novartis Vaccines and Diagnostics, Inc. |
Alphavirus-Vektoren für RSV- und PIV-Impfstoffe
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
EP3001990A1
(de)
|
2004-05-28 |
2016-04-06 |
Oryxe |
Mischung zur transdermalen abgabe von verbindungen mit niedrigem und hohem molekulargewicht
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
JP2008501693A
(ja)
*
|
2004-06-03 |
2008-01-24 |
アイシス ファーマシューティカルズ、インク. |
遺伝子調節で使用するための個別に調節された鎖を有する二本鎖組成物
|
CA2567789A1
(en)
*
|
2004-06-08 |
2006-08-03 |
Coley Pharmaceutical Gmbh |
Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
|
US8017779B2
(en)
*
|
2004-06-15 |
2011-09-13 |
3M Innovative Properties Company |
Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
WO2006009832A1
(en)
*
|
2004-06-18 |
2006-01-26 |
3M Innovative Properties Company |
Substituted imidazo ring systems and methods
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006038923A2
(en)
*
|
2004-06-18 |
2006-04-13 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US7915281B2
(en)
*
|
2004-06-18 |
2011-03-29 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
|
US7482158B2
(en)
*
|
2004-07-01 |
2009-01-27 |
Mathison Brian H |
Composite polynucleic acid therapeutics
|
EP1781325A2
(de)
*
|
2004-07-18 |
2007-05-09 |
CSL Limited |
Immunstimulierender komplex und oligonucleotidformulierungen zur induzierung verbesserter interferon-gamma-antworten
|
US20060025390A1
(en)
*
|
2004-07-28 |
2006-02-02 |
Roby Russell R |
Treatment of hormone allergy and related symptoms and disorders
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
DK1773884T3
(da)
|
2004-08-03 |
2012-05-21 |
Innate Pharma |
Terapeutiske og diagnostiske fremgangsmåder og sammensætninger til targeting af 4ig-b7-h3 og dets tilsvarende nk-celle-receptor
|
EP1786450A4
(de)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
Hiv-immunstimulatorische zusammensetzungen
|
US20090270443A1
(en)
*
|
2004-09-02 |
2009-10-29 |
Doris Stoermer |
1-amino imidazo-containing compounds and methods
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP1791858B1
(de)
|
2004-09-24 |
2010-04-21 |
Intercell AG |
Verändertes vp-1capsidprotein von parvovirus b19
|
JP2008000001A
(ja)
*
|
2004-09-30 |
2008-01-10 |
Osaka Univ |
免疫刺激オリゴヌクレオチドおよびその医薬用途
|
ES2531734T3
(es)
|
2004-10-06 |
2015-03-18 |
Medimmune, Llc |
Composiciones de vacuna para la gripe estables a temperaturas de refrigerador
|
AU2005294129B2
(en)
|
2004-10-08 |
2010-12-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention |
Modulation of replicative fitness by using less frequently used synonymous codons
|
US20070243215A1
(en)
*
|
2004-10-08 |
2007-10-18 |
Miller Richard L |
Adjuvant for Dna Vaccines
|
MY159370A
(en)
*
|
2004-10-20 |
2016-12-30 |
Coley Pharm Group Inc |
Semi-soft-class immunostimulatory oligonucleotides
|
EP1802335A2
(de)
|
2004-10-21 |
2007-07-04 |
Wyeth a Corporation of the State of Delaware |
Immunogene zusammensetzungen aus staphylococcus-epidermidis-polypeptid- und polynukleotid-antigenen
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP3034089A1
(de)
|
2004-11-02 |
2016-06-22 |
Archemix LLC |
Stabilisierte aptamere für einen aus plättchen gewonnenen wachstumsfaktor und deren verwendung als onkologietherapeutika
|
US7332324B2
(en)
|
2004-12-03 |
2008-02-19 |
University Of Toledo |
Attenuated vaccine useful for immunizations against Coccidioides spp. infections
|
EP1819364A4
(de)
*
|
2004-12-08 |
2010-12-29 |
3M Innovative Properties Co |
Immunmodulatorische zusammensetzungen, kombinationen und verfahren
|
WO2006065751A2
(en)
*
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
US8197817B2
(en)
|
2004-12-17 |
2012-06-12 |
Dana-Farber Cancer Institute, Inc. |
Regulation of mink in thymocytes and T lymphocytes
|
CA2592922A1
(en)
*
|
2004-12-29 |
2006-07-06 |
Mannkind Corporation |
Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
|
JP5543068B2
(ja)
*
|
2004-12-30 |
2014-07-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
AU2005321912B2
(en)
*
|
2004-12-30 |
2012-04-05 |
3M Innovative Properties Company |
Treatment for cutaneous metastases
|
CA2594674C
(en)
|
2004-12-30 |
2016-05-17 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
CN100485034C
(zh)
*
|
2005-01-28 |
2009-05-06 |
权滢周 |
从分支杆菌中提取的用于刺激免疫功能,治疗免疫相关性疾病,过敏性皮炎和/或保护正常免疫细胞的寡核苷酸
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
WO2006084251A2
(en)
|
2005-02-04 |
2006-08-10 |
Coley Pharmaceutical Group, Inc. |
Aqueous gel formulations containing immune reponse modifiers
|
WO2006086634A2
(en)
|
2005-02-11 |
2006-08-17 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
ATE552267T1
(de)
|
2005-02-18 |
2012-04-15 |
Novartis Vaccines & Diagnostic |
Immungene von uropathogenen escherichia coli
|
DK1858920T3
(en)
|
2005-02-18 |
2016-02-29 |
Glaxosmithkline Biolog Sa |
PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI
|
CA2598992A1
(en)
*
|
2005-02-24 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Immunostimulatory oligonucleotides
|
CN101171033A
(zh)
|
2005-03-04 |
2008-04-30 |
戴纳瓦克斯技术公司 |
包含具免疫刺激序列iss之寡核苷酸的疫苗:其中iss与抗原缀合并通过缓冲条件和其他赋形剂稳定
|
US8101345B1
(en)
|
2005-03-25 |
2012-01-24 |
Isis Pharmaceuticals, Inc. |
Proinflammatory nucleic acids
|
CA2602590A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
AU2006232377A1
(en)
|
2005-04-01 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
US20060229271A1
(en)
*
|
2005-04-08 |
2006-10-12 |
Coley Pharmaceutical Group, Inc. |
Methods for treating infectious disease exacerbated asthma
|
US7709001B2
(en)
|
2005-04-08 |
2010-05-04 |
Wyeth Llc |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
EP2425855A1
(de)
|
2005-04-08 |
2012-03-07 |
Wyeth LLC |
Multivalente Pneumokokken-Polysaccharidproteinkonjugatzusammensetzung
|
JP2008535862A
(ja)
*
|
2005-04-08 |
2008-09-04 |
キメリクス,インコーポレイテッド |
ポックスウイルス感染の治療のための化合物、組成物および方法
|
US20070003608A1
(en)
*
|
2005-04-08 |
2007-01-04 |
Almond Merrick R |
Compounds, compositions and methods for the treatment of viral infections and other medical disorders
|
CA2604683C
(en)
|
2005-04-12 |
2019-04-30 |
Duke University |
Method of inducing neutralizing antibodies to human immunodeficiency virus
|
EP1871411A4
(de)
|
2005-04-18 |
2010-07-21 |
Novartis Vaccines & Diagnostic |
Expression von hepatitis-b-virus-oberflächenantigen für impfstoffherstellung
|
JP2008539252A
(ja)
*
|
2005-04-25 |
2008-11-13 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫活性化組成物
|
CA2609788A1
(en)
*
|
2005-04-26 |
2006-11-02 |
Coley Pharmaceutical Gmbh |
Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
|
DE602006020867D1
(de)
|
2005-06-14 |
2011-05-05 |
Protox Therapeutics Inc |
Verfahren zur behandlung oder prävention gutartiger prostatahyperplasie unter verwendung modifizierter porenbildender proteine
|
MX2007016561A
(es)
|
2005-06-30 |
2008-03-10 |
Archemix Corp |
Materiales y metodos para la generacion de transcriptos de acido nucleico completamente modificados en la posicion 2.
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
EP2179737B1
(de)
|
2005-07-01 |
2013-08-14 |
Index Pharmaceuticals AB |
Modulierung der Reaktion auf Steroide
|
CA2612162C
(en)
|
2005-07-01 |
2016-05-17 |
Index Pharmaceuticals Ab |
Use of oligonucleotides in steroid refractory or steroid dependent inflammatory conditions
|
SG163583A1
(en)
*
|
2005-07-07 |
2010-08-30 |
Coley Pharm Group Inc |
Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
|
WO2007008904A2
(en)
|
2005-07-08 |
2007-01-18 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
|
JP2009501546A
(ja)
|
2005-07-18 |
2009-01-22 |
ノバルティス アーゲー |
Hcv複製についての小動物モデル
|
WO2007012285A1
(fr)
*
|
2005-07-28 |
2007-02-01 |
Changchun Huapu Biotechnology Co., Ltd. |
Desoxynucleosides monocatenaires resistant aux infections virales
|
EP1924692A2
(de)
*
|
2005-09-16 |
2008-05-28 |
Coley Pharmaceutical GmbH |
Modulierung von immunanregenden eigenschaften von short-interfering-ribonukleinsäure (sirna) durch nukleotidmodifizierung
|
EA013468B1
(ru)
*
|
2005-09-16 |
2010-04-30 |
Коли Фармасьютикал Гмбх |
Иммуностимулирующая одноцепочечная рибонуклеиновая кислота с фосфодиэфирным остовом
|
US20070081972A1
(en)
*
|
2005-09-30 |
2007-04-12 |
The University Of Iowa Research Foundation |
Polymer-based delivery system for immunotherapy of cancer
|
EP2357000A1
(de)
|
2005-10-18 |
2011-08-17 |
Novartis Vaccines and Diagnostics, Inc. |
Mukosale und systemische Immunisierungen mit Alphavirus-Replikonpartikeln
|
AU2006306805A1
(en)
|
2005-10-28 |
2007-05-03 |
Index Pharmaceuticals Ab |
Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
|
JP2009514850A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
アジュバントとして減少した量の水中油型エマルションを有するインフルエンザワクチン
|
ES2792398T3
(es)
|
2005-11-04 |
2020-11-11 |
Seqirus Uk Ltd |
Vacunas adyuvantadas con antígenos de no virión preparadas a partir de virus de la gripe cultivados en cultivo celular
|
EP1951299B1
(de)
|
2005-11-04 |
2012-01-04 |
Novartis Vaccines and Diagnostics S.r.l. |
Grippeimpfstoffe mit kombinationen aus teilchenförmigen adjuvantien und immunverstärkern
|
JP2009514839A
(ja)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
サイトカイン誘導剤を含むアジュバントインフルエンザワクチン
|
CN102864152B
(zh)
*
|
2005-11-07 |
2015-11-18 |
艾德拉药物股份有限公司 |
包含经修饰的免疫刺激性二核苷酸的基于寡核苷酸的化合物之免疫刺激特性
|
EP1969001A2
(de)
|
2005-11-22 |
2008-09-17 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus- und sapovirus-antigene
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
EP1957647B1
(de)
|
2005-11-25 |
2015-03-04 |
Zoetis Belgium S.A. |
Immunstimulierende oligoribonukleotide
|
US20070184068A1
(en)
|
2005-12-14 |
2007-08-09 |
Cytos Biotechnology Ag |
Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
CA2642152C
(en)
*
|
2006-02-15 |
2016-11-01 |
Coley Pharmaceutical Gmbh |
Compositions and methods for oligonucleotide formulations
|
WO2007100634A2
(en)
|
2006-02-22 |
2007-09-07 |
3M Innovative Properties Company |
Immune response modifier conjugates
|
EP2397855A3
(de)
|
2006-03-14 |
2012-03-14 |
Oregon Health and Science University |
Methoden zur Detektion einer Mycobakterium tuberculosis Infektion
|
EP2357184B1
(de)
|
2006-03-23 |
2015-02-25 |
Novartis AG |
Imidazochinoxalinverbindungen als Immunmodulatoren
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
EP2004226A1
(de)
|
2006-03-24 |
2008-12-24 |
Novartis Vaccines and Diagnostics GmbH & Co. KG |
Lagerung von grippeimpfstoffen ohne kühlung
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
WO2007119815A1
(ja)
|
2006-04-14 |
2007-10-25 |
Kyowa Hakko Kirin Co., Ltd. |
Toll様受容体9作動薬
|
TW200806315A
(en)
|
2006-04-26 |
2008-02-01 |
Wyeth Corp |
Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
|
DK2034015T3
(da)
*
|
2006-05-31 |
2012-10-15 |
Toray Industries |
Immunstimulerende oligonucleotid og farmaceutisk anvendelse heraf
|
WO2007143582A2
(en)
*
|
2006-06-05 |
2007-12-13 |
Baylor College Of Medicine |
Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
MX2008015529A
(es)
|
2006-06-12 |
2009-01-13 |
Cytos Biotechnology Ag |
Procesos para empacar oligonucleotidos en particulas similares a virus de bacteriofagos de arn.
|
KR101141333B1
(ko)
|
2006-06-20 |
2012-05-23 |
트랜스진 에스.에이. |
재조합 바이러스 백신
|
US8128921B2
(en)
*
|
2006-07-11 |
2012-03-06 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
US7906506B2
(en)
*
|
2006-07-12 |
2011-03-15 |
3M Innovative Properties Company |
Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
CA2659552A1
(en)
|
2006-08-16 |
2008-02-21 |
Novartis Ag |
Immunogens from uropathogenic escherichia coli
|
US20100010199A1
(en)
|
2006-09-11 |
2010-01-14 |
Novartis Ag |
Making influenza virus vaccines without using eggs
|
CN101517082B
(zh)
*
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
DE102006050655A1
(de)
*
|
2006-10-24 |
2008-04-30 |
Halmon Beheer B.V. |
Pharmazeutische Zusammensetzung zur Behandlung allergischer Erkrankungen
|
AU2007353120A1
(en)
*
|
2006-10-26 |
2008-11-20 |
Coley Pharmaceutical Gmbh |
Oligoribonucleotides and uses thereof
|
EP3029461B1
(de)
|
2006-11-01 |
2017-12-20 |
Ventana Medical Systems, Inc. |
Haptene, haptenkonjugate, zusammensetzungen daraus und verfahren für ihre herstellung und verwendung
|
WO2008057529A2
(en)
*
|
2006-11-06 |
2008-05-15 |
Coley Pharmaceutical Group, Inc. |
Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
|
CN104857512A
(zh)
|
2006-11-09 |
2015-08-26 |
戴纳瓦克斯技术公司 |
使用免疫刺激性寡核苷酸进行长期的疾病修饰
|
US20090285819A1
(en)
*
|
2006-11-15 |
2009-11-19 |
Functional Genetics, Inc. |
Methods and compositions for treating influenza
|
WO2008068631A2
(en)
|
2006-12-06 |
2008-06-12 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
AR064642A1
(es)
|
2006-12-22 |
2009-04-15 |
Wyeth Corp |
Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2444410A3
(de)
|
2007-02-28 |
2012-08-08 |
The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services |
Brachyurie-Polypeptide und Verwendungsverfahren
|
EP2139516A4
(de)
*
|
2007-04-13 |
2011-06-29 |
Univ Duke |
Verfahren zur induzierung neutralisierender antikörper gegen hiv
|
US8518903B2
(en)
|
2007-04-19 |
2013-08-27 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Use of toll-like receptor-9 agonists
|
US20100322949A1
(en)
|
2007-04-26 |
2010-12-23 |
Ludwig Institute For Cancer Research Ltd. |
Methods for diagnosing and treating astrocytomas
|
WO2008134077A1
(en)
*
|
2007-04-30 |
2008-11-06 |
Archemix Corp. |
Metabolic profile directed aptamer medicinal chemistry
|
AU2008252577A1
(en)
*
|
2007-05-17 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Class A oligonucleotides with immunostimulatory potency
|
WO2008142513A2
(en)
*
|
2007-05-18 |
2008-11-27 |
Coley Pharmaceutical Gmbh |
Phosphate-modified oligonucleotide analogs with immunostimulatory activity
|
AU2008262489B2
(en)
|
2007-05-23 |
2013-11-28 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
AR066676A1
(es)
*
|
2007-05-24 |
2009-09-02 |
Glaxosmithkline Biolog Sa |
Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
|
PL2185191T3
(pl)
|
2007-06-27 |
2013-02-28 |
Novartis Ag |
Szczepionki przeciwko grypie o małej zawartości dodatków
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
US7879812B2
(en)
|
2007-08-06 |
2011-02-01 |
University Of Iowa Research Foundation |
Immunomodulatory oligonucleotides and methods of use therefor
|
CA2697049A1
(en)
*
|
2007-08-21 |
2009-02-26 |
Dynavax Technologies Corporation |
Composition and methods of making and using influenza proteins
|
JP5653215B2
(ja)
|
2007-09-12 |
2015-01-14 |
ノバルティス アーゲー |
Gas57変異体抗原およびgas57抗体
|
RU2010112771A
(ru)
*
|
2007-10-09 |
2011-11-20 |
Коули Фармасьютикал ГмбХ (DE) |
Иммуностимулирующие аналоги олигонуклеотидов, содержащие модифицированные сахарные группировки
|
US20110014231A1
(en)
*
|
2007-11-05 |
2011-01-20 |
Mor Research Applications Ltd |
Anti-measles cancer immunotherapy
|
US8415361B2
(en)
|
2007-11-09 |
2013-04-09 |
The Salk Institute For Biological Studies |
Use of TAM receptor inhibitors as antimicrobials
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
WO2009076158A1
(en)
|
2007-12-07 |
2009-06-18 |
Novartis Ag |
Compositions for inducing immune responses
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
US20090175906A1
(en)
*
|
2007-12-21 |
2009-07-09 |
Wyeth |
Genetically Modified Attenuated Vesicular Stomatitis Virus, Compositions and Methods of use Thereof
|
BRPI0821240B8
(pt)
|
2007-12-21 |
2022-10-04 |
Novartis Ag |
formas mutantes de estreptolisina o
|
MX2010008148A
(es)
*
|
2008-01-25 |
2010-10-20 |
Chimerix Inc |
Métodos de tratamiento de infecciones virales.
|
PT2176408E
(pt)
*
|
2008-01-31 |
2015-04-23 |
Curevac Gmbh |
Ácidos nucleicos compreendendo a fórmula (nuglxmgnnv)a e os seus derivados como agentes/adjuvantes imunoestimuladores
|
EP2886551A3
(de)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningokokken-FHBP-Polypeptide
|
ES2557282T3
(es)
|
2008-03-10 |
2016-01-25 |
Children's Hospital & Research Center At Oakland |
Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
|
NZ587798A
(en)
|
2008-03-18 |
2013-06-28 |
Novartis Ag |
Improvements in the preparation of influenza virus vaccine antigens utilising a phosphate buffer
|
AU2009246169B2
(en)
|
2008-05-15 |
2015-01-22 |
Dynavax Technologies Corporation |
Long term disease modification using immunostimulatory oligonucleotides
|
US8222225B2
(en)
|
2008-05-21 |
2012-07-17 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating pneumoconiosis with oligodeoxynucleotides
|
CA2979353C
(en)
|
2008-06-05 |
2020-06-30 |
Ventana Medical Systems, Inc. |
Compositions comprising nanomaterials and method for using such compositions for histochemical processes
|
EP2650014A2
(de)
|
2008-06-20 |
2013-10-16 |
Wyeth LLC |
Zusammensetzungen und Verfahren zur Verwendung von ORF1358 von Beta-hämolytischen Streptokokken-stämmen
|
EP3552625A1
(de)
|
2008-06-27 |
2019-10-16 |
Zoetis Services LLC |
Neue adjuvante zusammensetzungen
|
TWI351288B
(en)
*
|
2008-07-04 |
2011-11-01 |
Univ Nat Pingtung Sci & Tech |
Cpg dna adjuvant in avian vaccines
|
US20110136897A1
(en)
*
|
2008-08-14 |
2011-06-09 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
AU2009294318B2
(en)
|
2008-09-18 |
2014-04-24 |
Novartis Ag |
Vaccine adjuvant combinations
|
CA2732750A1
(en)
|
2008-09-22 |
2010-03-25 |
The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs |
Methods for detecting a mycobacterium tuberculosis infection
|
NZ591925A
(en)
*
|
2008-10-16 |
2012-09-28 |
Internat Vaccine Inst |
Adjuvant composition comprising a host defense peptide, an immunostimulatory sequence and a polyanionic polymer
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
CN102203122A
(zh)
|
2008-11-05 |
2011-09-28 |
惠氏有限责任公司 |
用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
|
EP2346529B1
(de)
|
2008-11-12 |
2016-02-10 |
Theraclone Sciences, Inc. |
Humane m2e-peptid-immunogene
|
ES2616051T3
(es)
|
2008-12-02 |
2017-06-09 |
Wave Life Sciences Japan, Inc. |
Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
|
US8552165B2
(en)
*
|
2008-12-09 |
2013-10-08 |
Heather Davis |
Immunostimulatory oligonucleotides
|
SI2759306T1
(sl)
|
2008-12-09 |
2016-05-31 |
Coley Pharmaceutical Group, Inc. |
Imunostimulacijski oligonukleotidi
|
CN102245198B
(zh)
|
2008-12-09 |
2016-08-17 |
辉瑞疫苗有限责任公司 |
IgE CH3肽疫苗
|
US8585505B2
(en)
|
2008-12-15 |
2013-11-19 |
Tetris Online, Inc. |
Inter-game interactive hybrid asynchronous computer game infrastructure
|
BRPI1005670A8
(pt)
|
2009-01-05 |
2017-12-26 |
Epitogenesis Inc |
composições adjuvantes e processos de uso.
|
US20100233270A1
(en)
|
2009-01-08 |
2010-09-16 |
Northwestern University |
Delivery of Oligonucleotide-Functionalized Nanoparticles
|
US8465751B2
(en)
|
2009-01-12 |
2013-06-18 |
Novartis Ag |
Cna—B domain antigens in vaccines against gram positive bacteria
|
US8664183B2
(en)
|
2009-02-27 |
2014-03-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
SPANX-B polypeptides and their use
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
BRPI1009215B1
(pt)
|
2009-03-23 |
2019-10-29 |
Nanirx Inc |
composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
|
CA2756522C
(en)
|
2009-03-24 |
2018-06-26 |
Novartis Ag |
Adjuvanting meningococcal factor h binding protein
|
PL2411521T3
(pl)
|
2009-03-25 |
2015-08-31 |
Univ Texas |
Kompozycje do stymulacji wrodzonej odporności immunologicznej na patogeny u ssaków
|
RU2015117604A
(ru)
|
2009-04-03 |
2015-10-27 |
Эйдженус Инк. |
Способы получения и применения мультишаперон-антигенных комплексов
|
JP2013505201A
(ja)
|
2009-04-03 |
2013-02-14 |
デューク ユニバーシティー |
広域反応性中和抗hiv抗体を誘導するための配合物
|
EP2419129A2
(de)
|
2009-04-14 |
2012-02-22 |
Novartis AG |
Zusammensetzungen zur immunisierung gegen staphylococcus aerus
|
WO2010123569A2
(en)
*
|
2009-04-21 |
2010-10-28 |
Selecta Biosciences, Inc. |
Immunonanotherapeutics providing a th1-biased response
|
CA2757620C
(en)
|
2009-04-30 |
2016-04-26 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
EP2435094A2
(de)
|
2009-05-27 |
2012-04-04 |
Selecta Biosciences, Inc. |
Gezielt ausgerichtete synthetische nanoträger mit ph-sensitiver freisetzung von immunmodulatorischen stoffen
|
US9526778B2
(en)
|
2009-06-15 |
2016-12-27 |
Institut Pasteur De Lille |
Influenza vaccine, composition, and methods of use
|
TW201544119A
(zh)
|
2009-06-22 |
2015-12-01 |
Wyeth Llc |
組合物及製備金黃色葡萄球菌血清型5及8莢膜多醣結合物之免疫原性組合物之方法
|
PE20110023A1
(es)
|
2009-06-22 |
2011-01-31 |
Wyeth Llc |
Composiciones inmunogenicas de antigenos de staphylococcus aureus
|
AU2010270714B2
(en)
|
2009-07-06 |
2015-08-13 |
Wave Life Sciences Ltd. |
Novel nucleic acid prodrugs and methods use thereof
|
AR077757A1
(es)
|
2009-07-15 |
2011-09-21 |
Novartis Ag |
Composiciones de proteinas de fusion del virus sincicial respiratorio (rsv) y metodos para su preparacion
|
EP2464658B1
(de)
|
2009-07-16 |
2014-10-01 |
Novartis AG |
Detoxifizierte escherichia coli immunogene
|
WO2011007961A2
(en)
|
2009-07-17 |
2011-01-20 |
Industry Academic Cooperation Foundation, Hallym University |
Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
|
US8614200B2
(en)
|
2009-07-21 |
2013-12-24 |
Chimerix, Inc. |
Compounds, compositions and methods for treating ocular conditions
|
CA2768346A1
(en)
|
2009-07-30 |
2011-02-03 |
Pfizer Vaccines Llc |
Antigenic tau peptides and uses thereof
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
AU2010284329B2
(en)
*
|
2009-08-18 |
2015-04-16 |
Takeda Pharmaceutical Company Limited |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
US8598327B2
(en)
|
2009-08-18 |
2013-12-03 |
Baxter International Inc. |
Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
|
WO2011031298A1
(en)
|
2009-08-26 |
2011-03-17 |
Selecta Biosciences, Inc. |
Compositions that induce t cell help
|
CA2772104A1
(en)
|
2009-08-27 |
2011-03-03 |
Novartis Ag |
Hybrid polypeptides including meningococcal fhbp sequences
|
BR112012004276A2
(pt)
|
2009-08-27 |
2017-10-24 |
Novartis Ag |
adjuvante compreendendo alumínio, oligonucleotídeo e policátion
|
WO2011026111A1
(en)
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
HUE037416T2
(hu)
|
2009-09-03 |
2018-08-28 |
Pfizer Vaccines Llc |
PCSK9 vakcina
|
BR112012008338A2
(pt)
|
2009-09-10 |
2019-09-24 |
Novartis Ag |
combinação de vacinas contra doenças do trato respiratório.
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
AU2010302344A1
(en)
|
2009-09-30 |
2012-04-26 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
ES2812523T3
(es)
|
2009-09-30 |
2021-03-17 |
Glaxosmithkline Biologicals Sa |
Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
|
CN102782138A
(zh)
|
2009-10-07 |
2012-11-14 |
Uvic工业合伙公司 |
包含热敏性转基因的疫苗
|
US9181306B2
(en)
|
2009-10-16 |
2015-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
MX2012004850A
(es)
|
2009-10-27 |
2012-05-22 |
Novartis Ag |
Polipeptidos fhbp meningococicos modificados.
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP3263124A1
(de)
|
2009-11-20 |
2018-01-03 |
Oregon Health&Science University |
Verfahren zum hervorrufen einer immunantwort auf tuberkulose
|
CN102762224A
(zh)
|
2009-12-22 |
2012-10-31 |
塞尔德克斯医疗公司 |
疫苗组合物
|
EP3216789A1
(de)
|
2010-02-12 |
2017-09-13 |
Chimerix, Inc. |
Verfahren zur behandlung von vireninfektionen
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
US8685416B2
(en)
|
2010-03-02 |
2014-04-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of cancer
|
EA201290876A1
(ru)
|
2010-03-05 |
2013-03-29 |
Президент Энд Феллоуз Оф Гарвард Колледж |
Композиции индуцированных дендритных клеток и их использование
|
WO2011112599A2
(en)
|
2010-03-12 |
2011-09-15 |
The United States Of America, As Represented By The Secretary. Department Of Health & Human Services |
Immunogenic pote peptides and methods of use
|
CA2793510A1
(en)
|
2010-03-18 |
2012-02-16 |
Novartis Ag |
Adjuvanted vaccines for serogroup b meningococcus
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(de)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Verfahren zur erzeugung von virusähnlichen parvovirus-b19-partikeln
|
US9597326B2
(en)
|
2010-04-13 |
2017-03-21 |
Glaxosmithkline Biologicals Sa |
Benzonapthyridine compositions and uses thereof
|
EP2563367A4
(de)
|
2010-04-26 |
2013-12-04 |
Chimerix Inc |
Verfahren zur behandlung von retroviren-infektionen und entsprechende dosierungspläne
|
DK2569436T3
(en)
|
2010-05-14 |
2018-03-05 |
Univ Oregon Health & Science |
RECOMBINANT HCMV AND RHCMV VECTORS AND APPLICATIONS THEREOF
|
BR112012029912A2
(pt)
|
2010-05-26 |
2016-11-16 |
Selecta Biosciences Inc |
vácinas de combinação de nanotransportadores sintéticos
|
BR112012030337B1
(pt)
|
2010-05-28 |
2021-04-27 |
Coley Pharmaceutical Group, Inc |
Vacina compreendendo um ou mais oligonucleotídeo(s) de cpg isolado(s) ou um agonista de tlr e colesterol, e uso da mesma
|
MX342405B
(es)
|
2010-06-03 |
2016-09-28 |
Pharmacyclics Inc |
El uso de inhibidores de la tirosina quinasa de bruton (btk).
|
CN102933229A
(zh)
|
2010-06-04 |
2013-02-13 |
惠氏有限责任公司 |
疫苗制剂
|
CA2800774A1
(en)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Ige ch3 peptide vaccine
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
WO2011161653A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
EP3153578A1
(de)
|
2010-07-06 |
2017-04-12 |
Novartis Ag |
Immunogene zusammensetzungen aus norovirus und verfahren
|
CN103189071A
(zh)
|
2010-08-23 |
2013-07-03 |
惠氏有限责任公司 |
脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
|
WO2012032489A1
(en)
|
2010-09-10 |
2012-03-15 |
Wyeth Llc |
Non-lipidated variants of neisseria meningitidis orf2086 antigens
|
US8883171B2
(en)
|
2010-09-14 |
2014-11-11 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for influenza
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US10668092B2
(en)
|
2010-09-24 |
2020-06-02 |
The John Hopkins University |
Compositions and methods for treatment of inflammatory disorders
|
US10428019B2
(en)
|
2010-09-24 |
2019-10-01 |
Wave Life Sciences Ltd. |
Chiral auxiliaries
|
US9072760B2
(en)
|
2010-09-24 |
2015-07-07 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
EP2640190A4
(de)
|
2010-11-05 |
2016-05-11 |
Selecta Biosciences Inc |
Modifizierte nikotinische verbindungen und zugehörige verfahren
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
EP2468866A1
(de)
*
|
2010-12-21 |
2012-06-27 |
Index Pharmaceuticals AB |
Biologisch aktive Oligonukleotide zur Modulation des Immunsystems
|
ES2722204T3
(es)
|
2010-12-22 |
2019-08-08 |
Bayer Ip Gmbh |
Respuesta inmune mejorada en especies bovinas
|
MX350170B
(es)
|
2010-12-22 |
2017-08-28 |
Wyeth Llc |
Composición inmunogénica estable de antígenos de staphylococcus aureus.
|
WO2012088425A2
(en)
|
2010-12-22 |
2012-06-28 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
|
GB201021867D0
(en)
|
2010-12-23 |
2011-02-02 |
Mologen Ag |
Non-coding immunomodulatory DNA construct
|
WO2012085668A2
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
EP2471926A3
(de)
*
|
2010-12-30 |
2012-07-11 |
Intervet International BV |
Immunstimulierende Oligodeoxynukleotide
|
EP4144368A1
(de)
|
2011-01-26 |
2023-03-08 |
GlaxoSmithKline Biologicals S.A. |
Rsv-immunisierungstherapie
|
EP2673364A1
(de)
|
2011-02-11 |
2013-12-18 |
Baxter International Inc |
Aptamere für einen gewebefaktorpfadhemmer und ihre verwendung als therapiemittel für blutungsstörungen
|
EP2680883B1
(de)
|
2011-03-02 |
2018-09-05 |
Pfizer Inc |
Pcsk9-impfstoff
|
MX350795B
(es)
|
2011-04-08 |
2017-09-19 |
Inmune Design Corp |
Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares.
|
US9452212B2
(en)
|
2011-04-14 |
2016-09-27 |
Dynavax Technologies Corporation |
Methods and compositions for eliciting an immune response against hepatitis B virus
|
US20120288515A1
(en)
|
2011-04-27 |
2012-11-15 |
Immune Design Corp. |
Synthetic long peptide (slp)-based vaccines
|
ES2782119T3
(es)
|
2011-05-13 |
2020-09-10 |
Glaxosmithkline Biologicals Sa |
Antígenos de F de prefusión del VRS
|
FR2975600B1
(fr)
|
2011-05-24 |
2013-07-05 |
Assist Publ Hopitaux De Paris |
Agents pour le traitement de tumeurs
|
BR112013029966A2
(pt)
*
|
2011-05-26 |
2017-01-31 |
Intervet Int Bv |
oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa
|
WO2012167053A1
(en)
|
2011-06-01 |
2012-12-06 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
AU2012262014B2
(en)
|
2011-06-01 |
2016-07-14 |
Janus Biotherapeutics, Inc. |
Novel immune system modulators
|
CA2838158C
(en)
|
2011-06-03 |
2019-07-16 |
3M Innovative Properties Company |
Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
|
MX355623B
(es)
|
2011-06-03 |
2018-04-25 |
3M Innovative Properties Co |
Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
|
US8697085B2
(en)
|
2011-06-17 |
2014-04-15 |
University Of Tennessee Research Foundation |
Group A Streptococcus multivalent vaccine
|
KR20140047069A
(ko)
|
2011-06-20 |
2014-04-21 |
유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 |
계산에 최적화된 광범위 반응을 나타내는 h1n1 인플루엔자를 위한 항원
|
ITMI20111182A1
(it)
|
2011-06-28 |
2012-12-29 |
Canio Buonavoglia |
Vaccino per coronavirus canino
|
CA2841047A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic compositions and uses thereof
|
CA2840989A1
(en)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Immunogenic combination compositions and uses thereof
|
CN103764171B
(zh)
|
2011-07-08 |
2016-08-17 |
诺华股份有限公司 |
酪氨酸连接方法
|
WO2013007703A1
(en)
*
|
2011-07-08 |
2013-01-17 |
Universität Zürich |
CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
|
EP2734208B1
(de)
|
2011-07-19 |
2017-03-01 |
Wave Life Sciences Ltd. |
Verfahren zur synthese von funktionalisierten nukleinsäuren
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
EP2736921B1
(de)
|
2011-07-25 |
2018-06-27 |
GlaxoSmithKline Biologicals SA |
Zusammensetzungen und verfahren zum testen der funktionellen immunogenität von parvovirus-impfstoffen
|
WO2013019669A2
(en)
|
2011-07-29 |
2013-02-07 |
Selecta Biosciences, Inc. |
Synthetic nanocarriers that generate humoral and cytotoxic t lymphocyte (ctl) immune responses
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2013039792A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Immunogens based on an hiv-1 gp120 v1v2 epitope
|
ES2732708T3
(es)
|
2011-09-14 |
2019-11-25 |
Glaxosmithkline Biologicals Sa |
Procedimientos de fabricación de glucoconjugados de sacárido-proteína
|
EP2755994A2
(de)
|
2011-09-14 |
2014-07-23 |
Novartis AG |
Impfstoffkombination gegen escherichia coli
|
US20140234360A1
(en)
|
2011-09-30 |
2014-08-21 |
The United States of America, as represented by the Secretary, Dept.of Health and Human Services |
Influenza vaccine
|
EP2763677B1
(de)
|
2011-10-04 |
2020-02-26 |
Janus Biotherapeutics, Inc. |
Neue immunsystemmodulatoren auf imidazolchinolin-basis
|
EP3269728B1
(de)
|
2011-10-20 |
2020-12-16 |
The Government of The United States of America as represented by The Secretary, Department of Health and Human Services |
E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
BR112014013876A2
(pt)
|
2011-12-08 |
2019-09-24 |
Novartis Ag |
vacina à base de toxina de clostridium difficile
|
NZ625592A
(en)
|
2012-01-16 |
2016-09-30 |
Elizabeth Mckenna |
Compositions and methods for the treatment of hepatic diseases and disorders
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
US9234008B2
(en)
|
2012-02-07 |
2016-01-12 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Computationally optimized broadly reactive antigens for H3N2, H2N2, and B influenza viruses
|
CA2863949C
(en)
|
2012-02-13 |
2021-06-29 |
University Of Pittsburgh-Of The Commonwealth System Of Higher Education |
Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
|
WO2013124473A1
(en)
|
2012-02-24 |
2013-08-29 |
Novartis Ag |
Pilus proteins and compositions
|
AU2013229063B2
(en)
|
2012-03-09 |
2016-10-06 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
CA2866185C
(en)
|
2012-03-23 |
2021-04-06 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Pathogenic phlebovirus isolates and compositions and methods of use
|
WO2013163176A1
(en)
|
2012-04-23 |
2013-10-31 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
CN108671228A
(zh)
|
2012-04-26 |
2018-10-19 |
诺华股份有限公司 |
抗原和抗原组合
|
WO2013162828A1
(en)
|
2012-04-27 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Use of cpg oligonucleotides co-formulated with an antibiotic to accelarate wound healing
|
SG11201406592QA
(en)
|
2012-05-04 |
2014-11-27 |
Pfizer |
Prostate-associated antigens and vaccine-based immunotherapy regimens
|
CA2874210A1
(en)
|
2012-05-22 |
2013-11-28 |
Novartis Ag |
Meningococcus serogroup x conjugate
|
WO2013177291A1
(en)
|
2012-05-23 |
2013-11-28 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Salmonella typhi ty21a expressing yersinia pestis f1-v fusion protein and uses thereof
|
CN104428008B
(zh)
|
2012-05-24 |
2020-10-09 |
美国政府(由卫生和人类服务部的部长所代表) |
多价脑膜炎球菌缀合物及制备缀合物的方法
|
WO2013192144A2
(en)
|
2012-06-19 |
2013-12-27 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Rift valley fever virus replicon particles and use thereof
|
CN104428494B
(zh)
|
2012-06-19 |
2019-03-22 |
沃尔沃拉斯特瓦格纳公司 |
用于控制气流的装置、排气后处理系统和用于推进车辆的系统
|
KR102057217B1
(ko)
|
2012-06-20 |
2020-01-22 |
에스케이바이오사이언스 주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
MX2015000577A
(es)
|
2012-07-13 |
2015-08-14 |
Wave Life Sciences Pte Ltd |
Control quiral.
|
JP6246121B2
(ja)
*
|
2012-07-13 |
2017-12-13 |
株式会社新日本科学 |
キラル核酸アジュバント
|
CN107011400B
(zh)
|
2012-07-13 |
2021-05-25 |
波涛生命科学有限公司 |
不对称辅助基团
|
MX2015000789A
(es)
|
2012-07-19 |
2015-05-07 |
Zoetis Llc |
Composiciones de virus de la gripe bovina.
|
AU2013293087B2
(en)
|
2012-07-24 |
2017-08-31 |
Pharmacyclics Llc |
Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
|
WO2014018724A1
(en)
|
2012-07-27 |
2014-01-30 |
Zoetis Llc |
Tick toxin compositions
|
HUE049531T2
(hu)
|
2012-08-16 |
2020-10-28 |
Pfizer |
Glikokonjugációs eljárások és kompozíciók
|
EP3639851A1
(de)
|
2012-09-04 |
2020-04-22 |
Bavarian Nordic A/S |
Verfahren und zusammensetzungen zur verbesserung von impfstoffimmunreaktionen
|
WO2014043535A1
(en)
|
2012-09-14 |
2014-03-20 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions for the treatment of cancer
|
US20150224181A1
(en)
|
2012-09-14 |
2015-08-13 |
The United States Of America As Represented By The Secretary Department Of Health And Human Se |
Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
|
CA2882382A1
(en)
|
2012-09-18 |
2014-03-27 |
Novartis Ag |
Outer membrane vesicles
|
WO2014047588A1
(en)
|
2012-09-21 |
2014-03-27 |
Elizabeth Mckenna |
Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
|
WO2014052453A1
(en)
*
|
2012-09-25 |
2014-04-03 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Oral therapy of necrotizing enterocolitis
|
EP2903638B1
(de)
|
2012-10-03 |
2019-12-18 |
GlaxoSmithKline Biologicals SA |
Immunogene zusammensetzung
|
KR20150080592A
(ko)
|
2012-11-02 |
2015-07-09 |
파마시클릭스, 인코포레이티드 |
Tec 패밀리 키나제 억제제 애쥬번트 요법
|
WO2014074785A1
(en)
|
2012-11-08 |
2014-05-15 |
Ludwig Institute For Cancer Research Ltd. |
Methods of predicting outcome and treating breast cancer
|
KR20140075196A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
KR20140075201A
(ko)
|
2012-12-11 |
2014-06-19 |
에스케이케미칼주식회사 |
다가 폐렴구균 다당류-단백질 접합체 조성물
|
TWI465241B
(zh)
|
2012-12-19 |
2014-12-21 |
Ind Tech Res Inst |
圓柏(Juniperus chinensis)萃取物或木酚素(lignan)用於製造抑制血管新生之藥物的用途
|
WO2014097099A2
(en)
|
2012-12-20 |
2014-06-26 |
Pfizer Inc. |
Glycoconjugation process
|
JP2016507520A
(ja)
|
2013-01-23 |
2016-03-10 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
安定化されたb型肝炎コアポリペプチド
|
JP6494527B2
(ja)
|
2013-02-07 |
2019-04-03 |
ザ チルドレンズ メディカル センター コーポレーション |
肺炎球菌のコロニー形成および/または疾患からの保護を提供するタンパク質抗原
|
CA2903716C
(en)
|
2013-03-08 |
2019-04-09 |
Pfizer Inc. |
Immunogenic fusion polypeptides
|
AU2014236340B2
(en)
|
2013-03-14 |
2019-01-17 |
Massachusetts Institute Of Technology |
Nanoparticle-based compositions
|
JP2016512841A
(ja)
|
2013-03-15 |
2016-05-09 |
ゾエティス・サービシーズ・エルエルシー |
多価ワクチンによるb.トレハロシ感染に対するウシの干渉効果
|
DE102013004595A1
(de)
|
2013-03-15 |
2014-09-18 |
Emergent Product Development Germany Gmbh |
RSV-Impfstoffe
|
KR102233251B1
(ko)
|
2013-04-03 |
2021-03-26 |
엔-폴드 엘엘씨 |
신규 나노입자 조성물
|
EP2986717A1
(de)
|
2013-04-19 |
2016-02-24 |
The Regents of The University of California |
Lone-star-virus
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
CN103550783A
(zh)
*
|
2013-04-27 |
2014-02-05 |
中国人民解放军军事医学科学院放射与辐射医学研究所 |
一种核酸类药物靶向递送系统及其制备方法
|
CA2909586C
(en)
|
2013-05-15 |
2021-08-31 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
WO2014201245A1
(en)
|
2013-06-12 |
2014-12-18 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
|
TWI535451B
(zh)
*
|
2013-07-19 |
2016-06-01 |
財團法人國家衛生研究院 |
CpG寡去氧核苷酸、包含其之免疫組合物及組合物用於製備治療以刺激免疫反應的藥物之用途
|
CA2919268C
(en)
|
2013-07-25 |
2023-09-05 |
Exicure, Inc. |
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
EP3632458A1
(de)
|
2013-07-26 |
2020-04-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verbindungen und pharmazeutische zusammensetzungen zur behandlung von bakterieninfektionen
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
EP3049105B1
(de)
|
2013-09-19 |
2020-12-30 |
Moredun Research Institute |
Impfstoff
|
WO2015048635A1
(en)
|
2013-09-27 |
2015-04-02 |
Duke University |
Mper-liposome conjugates and uses thereof
|
WO2015048785A2
(en)
|
2013-09-30 |
2015-04-02 |
Los Alamos National Security, Llc |
Mosaic conserved region hiv immunogenic polypeptides
|
CA2926221A1
(en)
|
2013-10-04 |
2015-04-09 |
Pin Pharma, Inc. |
Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
|
CA2928908C
(en)
|
2013-11-01 |
2021-01-12 |
Pfizer Inc. |
Vectors for expression of prostate-associated antigens
|
EP2870974A1
(de)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella-Konjugatimpfstoffe
|
HUE056105T2
(hu)
|
2013-11-28 |
2022-01-28 |
Bavarian Nordic As |
Készítmények és eljárások fokozott immunválasz indukálására poxvírusvektorok alkalmazásával
|
CN105939699B
(zh)
|
2013-12-03 |
2020-10-02 |
西北大学 |
脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
|
AU2014361788B2
(en)
|
2013-12-13 |
2019-10-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Multi-epitope TARP peptide vaccine and uses thereof
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
US10149905B2
(en)
|
2014-01-15 |
2018-12-11 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
|
US10144933B2
(en)
|
2014-01-15 |
2018-12-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
|
US10322173B2
(en)
|
2014-01-15 |
2019-06-18 |
Shin Nippon Biomedical Laboratories, Ltd. |
Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
|
KR102423317B1
(ko)
|
2014-01-16 |
2022-07-22 |
웨이브 라이프 사이언시스 리미티드 |
키랄 디자인
|
CR20160369A
(es)
|
2014-01-21 |
2016-10-05 |
Immune Desing Corp |
Composiciones para uso en el tratamiento de afecciones alérgicas
|
BR112016015525A2
(pt)
|
2014-01-21 |
2017-10-24 |
Pfizer |
composições imunogênicas compreendendo antígenos sacarídeos capsulares conjugados e uso
|
KR20210032013A
(ko)
|
2014-01-21 |
2021-03-23 |
화이자 인코포레이티드 |
스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
|
EP3096783B1
(de)
|
2014-01-21 |
2021-07-07 |
Pfizer Inc. |
Kapsulare polysaccharide aus streptococcus pneumoniae und konjugate davon
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2016130569A1
(en)
|
2015-02-09 |
2016-08-18 |
Mj Biologics, Inc. |
A composition comprising pedv antigens and methods for making and using the composition
|
EP3104877B1
(de)
|
2014-02-11 |
2020-01-22 |
The USA, as represented by The Secretary, Department of Health and Human Services |
Pcsk9-impfstoff und verfahren zur verwendung davon
|
EP3443983B1
(de)
|
2014-02-14 |
2022-07-20 |
Pfizer Inc. |
Immunogene glykoproteinkonjugate
|
GB2523187A
(en)
|
2014-02-18 |
2015-08-19 |
Mologen Ag |
Covalently closed non-coding immunomodulatory DNA construct
|
WO2015130584A2
(en)
|
2014-02-25 |
2015-09-03 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
BR112016019837A2
(pt)
|
2014-02-28 |
2017-10-17 |
Bayer Animal Health Gmbh |
plasmídeos imunoestimuladores
|
CN106535930A
(zh)
|
2014-03-11 |
2017-03-22 |
明尼苏达大学董事会 |
猪流行性腹泻病毒疫苗及其使用方法
|
WO2015143400A1
(en)
|
2014-03-20 |
2015-09-24 |
Pharmacyclics, Inc. |
Phospholipase c gamma 2 and resistance associated mutations
|
EA037818B1
(ru)
|
2014-03-26 |
2021-05-25 |
Глаксосмитклайн Байолоджикалс С.А. |
Мутантные стафилококковые антигены
|
US9549914B2
(en)
|
2014-04-03 |
2017-01-24 |
The Johns Hopkins University |
Treatment of human cytomegalovirus by modulating Wnt
|
WO2015164798A1
(en)
|
2014-04-25 |
2015-10-29 |
Tria Bioscience Corp. |
Synthetic hapten carrier compositions and methods
|
EP3145495A4
(de)
*
|
2014-05-23 |
2018-01-17 |
Cauchon, Gregory |
Beschichtungsverfahren und -materialien
|
US20170121373A1
(en)
|
2014-05-30 |
2017-05-04 |
Sanofi Pasteur Inc. |
Expression and conformational analysis of engineered influenza hemagglutinin
|
TR201908550T4
(tr)
|
2014-06-04 |
2019-07-22 |
Exicure Inc |
Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
|
EA201692512A1
(ru)
|
2014-06-25 |
2017-07-31 |
Селекта Байосайенсиз, Инк. |
Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
|
EP3169352A1
(de)
|
2014-07-15 |
2017-05-24 |
Immune Design Corp. |
Prime-boost-therapieschemata mit einem tlr4-agonist-adjuvans und einem lentivirusvektor
|
EP3183251A4
(de)
|
2014-08-22 |
2017-12-27 |
Janus Biotherapeutics, Inc. |
Neuartige n2,n4,n7,6-tetrasubstituerte pteridin-2,4,7-triamin- und 2,4,6,7-ted pteridin-verbindungen und verfahren zur synthese und verwendung davon
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
MX2017004448A
(es)
|
2014-10-06 |
2017-10-23 |
Exicure Inc |
Compuestos anti-factor de necrosis tumoral (tnf).
|
US20160129097A1
(en)
*
|
2014-11-06 |
2016-05-12 |
Jeremy Delk |
Method of processing a veterinary tumor vaccine and a veterinary tumor vaccine processing kit
|
JP2017537619A
(ja)
|
2014-11-21 |
2017-12-21 |
ノースウェスタン ユニバーシティ |
球状核酸ナノ粒子複合体の配列特異的細胞内取込
|
JP6536964B2
(ja)
*
|
2014-12-26 |
2019-07-03 |
国立研究開発法人医薬基盤・健康・栄養研究所 |
免疫賦活活性を有する核酸多糖複合体の抗腫瘍薬としての応用
|
PT3240801T
(pt)
|
2014-12-31 |
2021-02-18 |
Checkmate Pharmaceuticals Inc |
Imunoterapia antitumoral combinada
|
DK3244917T3
(da)
|
2015-01-15 |
2023-05-22 |
Pfizer |
Immunogene sammensætninger til anvendelse i pneumokokvacciner
|
CN114699518A
(zh)
|
2015-01-16 |
2022-07-05 |
硕腾服务有限责任公司 |
口蹄疫疫苗
|
US20180036334A1
(en)
|
2015-02-13 |
2018-02-08 |
Icahn School Of Medicine At Mount Sinai |
Rna containing compositions and methods of their use
|
RU2723045C2
(ru)
|
2015-02-19 |
2020-06-08 |
Пфайзер Инк. |
Композиции neisseria meningitidis и способы их получения
|
ES2711893T3
(es)
|
2015-03-12 |
2019-05-08 |
Zoetis Services Llc |
Procedimientos y composiciones de la pirrolisina
|
NZ736238A
(en)
|
2015-05-04 |
2022-07-01 |
Pfizer |
Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
WO2016183371A1
(en)
|
2015-05-13 |
2016-11-17 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Methods for the treatment or prevention of ischemic tissue damage
|
IL293135A
(en)
|
2015-05-13 |
2022-07-01 |
Agenus Inc |
A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
|
CA2987939A1
(en)
|
2015-06-02 |
2016-12-08 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
EP3650043A3
(de)
|
2015-06-09 |
2020-07-29 |
The Board of Regents of the University of Oklahoma |
Zusammensetzungen und behandlungen für haemophilus influenzae
|
WO2016201224A1
(en)
|
2015-06-10 |
2016-12-15 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Processes for production and purification of nucleic acid-containing compositions
|
EP3313439A2
(de)
|
2015-06-26 |
2018-05-02 |
Seqirus UK Limited |
Antigenetisch angepasste influenza-impfstoffe
|
US10449212B2
(en)
|
2015-07-09 |
2019-10-22 |
National Institute For Materials Science |
Immunostimulating oligonucleotide complex
|
IL303998A
(en)
|
2015-07-21 |
2023-08-01 |
Pfizer |
Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
|
AU2016302436B2
(en)
|
2015-07-31 |
2022-03-03 |
Bayer Animal Health Gmbh |
Enhanced immune response in porcine species
|
CA2995101A1
(en)
|
2015-08-14 |
2017-02-23 |
Zoetis Services Llc |
Mycoplasma bovis compositions
|
WO2017040885A1
(en)
|
2015-09-03 |
2017-03-09 |
The Board Of Regents Of The University Of Oklahoma |
Peptide inhibitors of clostridium difficile tcdb toxin
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
US11260018B2
(en)
|
2015-09-17 |
2022-03-01 |
Jrx Biotechnology, Inc. |
Approaches for improving skin hydration and moisturization
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
US10548970B2
(en)
|
2015-10-05 |
2020-02-04 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Human rotavirus G9P[6] strain and use as a vaccine
|
CA3002685A1
(en)
|
2015-10-30 |
2017-05-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for the treatment of her2-expressing solid tumors
|
EP3377098A1
(de)
|
2015-11-20 |
2018-09-26 |
Pfizer Inc |
Immunogene zusammensetzungen zur verwendung in pneumokokkenimpfstoffen
|
CA3006779A1
(en)
|
2015-12-09 |
2017-06-15 |
Admedus Vaccines Pty Ltd |
Immunomodulating composition for treatment
|
EP3402878A1
(de)
|
2016-01-11 |
2018-11-21 |
Zoetis Services LLC |
Neuartige impfstoffzusammensetzungen mit kreuzschutz für das porzine epidemische diarrhoevirus
|
CA3009928A1
(en)
|
2016-01-29 |
2017-08-03 |
Bavarian Nordic A/S |
Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine
|
WO2017189448A1
(en)
|
2016-04-25 |
2017-11-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bivalent immunogenic conjugate for malaria and typhoid
|
WO2017192874A1
(en)
|
2016-05-04 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Albumin-binding immunomodulatory compositions and methods of use thereof
|
WO2017201390A1
(en)
|
2016-05-19 |
2017-11-23 |
The Regents Of The University Of Michigan |
Novel adjuvant compositions
|
US11033615B2
(en)
|
2016-05-31 |
2021-06-15 |
The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland |
Zika virus vaccine and methods of production
|
CA3026096A1
(en)
|
2016-06-02 |
2017-12-07 |
Sanofi Pasteur Inc. |
Engineered influenza antigenic polypeptides and immunogenic compositions thereof
|
SG11201810758WA
(en)
|
2016-06-03 |
2018-12-28 |
Sanofi Pasteur Inc |
Modification of engineered influenza hemagglutinin polypeptides
|
BR112018075513A2
(pt)
|
2016-06-13 |
2019-10-01 |
Us Health |
ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
|
WO2017220753A1
(en)
|
2016-06-22 |
2017-12-28 |
MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumococcal polysaccharide-protein conjugate composition
|
EP3269385A1
(de)
|
2016-07-12 |
2018-01-17 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
|
WO2018009604A1
(en)
|
2016-07-08 |
2018-01-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric dengue/zika viruses live-attenuated zika virus vaccines
|
US10632185B2
(en)
|
2016-07-08 |
2020-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric west nile/zika viruses and methods of use
|
MX2019001342A
(es)
|
2016-08-05 |
2019-07-04 |
Sanofi Pasteur Inc |
Composicion de conjugado de proteina-polisacarido de neumococo multivalente.
|
EA039427B1
(ru)
|
2016-08-05 |
2022-01-26 |
Санофи Пастер Инк. |
Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция
|
US10182146B2
(en)
*
|
2016-08-22 |
2019-01-15 |
Nice Ltd. |
System and method for dynamic redundant call recording
|
WO2018039629A2
(en)
|
2016-08-25 |
2018-03-01 |
Northwestern University |
Micellar spherical nucleic acids from thermoresponsive, traceless templates
|
JP7138094B2
(ja)
|
2016-08-25 |
2022-09-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
マクロファージ活性化剤と組み合わせた抗csf-1r抗体の間欠投与
|
US10172933B2
(en)
|
2016-10-31 |
2019-01-08 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Mosaic vaccines for serotype a foot-and-mouth disease virus
|
US10751402B2
(en)
|
2016-11-09 |
2020-08-25 |
Pfizer Inc. |
Immunogenic compositions and uses thereof
|
JP7304287B2
(ja)
|
2016-12-22 |
2023-07-06 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗pd-l1/pd1治療の不成功後の、抗pd-l1抗体との組み合わせでの抗csf-1r抗体を用いた腫瘍の治療
|
EP3570879B1
(de)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Immunogene zusammensetzung zur verwendung als pneumokokken-impfstoff
|
CN110225757A
(zh)
|
2017-01-31 |
2019-09-10 |
默沙东公司 |
由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
|
US10183070B2
(en)
|
2017-01-31 |
2019-01-22 |
Pfizer Inc. |
Neisseria meningitidis compositions and methods thereof
|
US11623945B2
(en)
|
2017-02-06 |
2023-04-11 |
The United States Of America, As Represented By The Secretary Of Agriculture |
Immunostimulating compositions and uses therefore
|
GB201703529D0
(en)
|
2017-03-06 |
2017-04-19 |
Cambridge Entpr Ltd |
Vaccine composition
|
WO2018183666A1
(en)
|
2017-03-31 |
2018-10-04 |
Boston Medical Center Corporation |
Methods and compositions using highly converved pneumococcal surface proteins
|
WO2018201090A1
(en)
|
2017-04-28 |
2018-11-01 |
Exicure, Inc. |
Synthesis of spherical nucleic acids using lipophilic moieties
|
CA3066915A1
(en)
|
2017-06-11 |
2018-12-20 |
Molecular Express, Inc. |
Methods and compositions for substance use disorder vaccine formulations and uses thereof
|
JP2020525540A
(ja)
|
2017-06-23 |
2020-08-27 |
ノソコミアル ヴァクスィーン コーポレイション |
免疫原性組成物
|
BR112020001255A2
(pt)
|
2017-07-21 |
2020-07-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
composições imunogênicas de neisseria meningitidis
|
JP7438102B2
(ja)
|
2017-09-07 |
2024-02-26 |
メルク・シャープ・アンド・ドーム・エルエルシー |
肺炎球菌多糖体および免疫原性多糖体-キャリアタンパク質コンジュゲートでのその使用
|
CA3075219A1
(en)
|
2017-09-08 |
2019-03-14 |
Mina Therapeutics Limited |
Hnf4a sarna compositions and methods of use
|
EP3690030A4
(de)
|
2017-09-28 |
2021-06-23 |
Industry-Academic Cooperation Foundation, Yonsei University |
Verfahren zur herstellung von aus myeloid abgeleiteten suppressorzellen, damit hergestellte suppressorzellen aus myeolid und deren verwendungen
|
WO2019090138A2
(en)
|
2017-11-04 |
2019-05-09 |
Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno |
Immunogenic conjugates and methods of use thereof
|
AR114154A1
(es)
|
2017-12-06 |
2020-07-29 |
Merck Sharp & Dohme |
Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y métodos de uso de estos
|
WO2019126197A1
(en)
|
2017-12-18 |
2019-06-27 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bacterial polysaccharide-conjugated carrier proteins and use thereof
|
KR20200101954A
(ko)
|
2017-12-19 |
2020-08-28 |
메사추세츠 인스티튜트 오브 테크놀로지 |
항원-아주반트 커플링 시약 및 사용 방법
|
WO2019143955A1
(en)
|
2018-01-22 |
2019-07-25 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Broadly protective inactivated influenza virus vaccine
|
RU2020128440A
(ru)
|
2018-02-28 |
2022-03-28 |
Пфайзер Инк. |
Варианты il-15 и их применения
|
MX2020009149A
(es)
*
|
2018-03-02 |
2021-01-15 |
Elicio Therapeutics Inc |
Compuestos que incluyen una secuencia de kras mutante y un lipido y usos de los mismos.
|
US11633471B2
(en)
|
2018-03-06 |
2023-04-25 |
Unm Rainforest Innovations |
Compositions and methods for reducing serum triglycerides
|
CN112189019A
(zh)
|
2018-03-28 |
2021-01-05 |
圣诺菲·帕斯图尔公司 |
产生包含血凝素的广泛保护性疫苗组合物的方法
|
JP2021519598A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイSanofi |
抗原性エプスタインバーウイルスポリペプチド
|
CA3095174A1
(en)
|
2018-04-03 |
2019-10-10 |
Sanofi |
Antigenic ospa polypeptides
|
KR20210018206A
(ko)
|
2018-04-03 |
2021-02-17 |
사노피 |
항원성 호흡기 세포융합 바이러스 폴리펩타이드
|
JP2021519600A
(ja)
|
2018-04-03 |
2021-08-12 |
サノフイSanofi |
抗原性インフルエンザ−フェリチンポリペプチド
|
CN112512564A
(zh)
|
2018-04-03 |
2021-03-16 |
赛诺菲 |
铁蛋白蛋白
|
TWI816396B
(zh)
|
2018-05-23 |
2023-09-21 |
美商輝瑞大藥廠 |
特異性針對gucy2c之抗體及其用途
|
JP7384835B2
(ja)
|
2018-05-23 |
2023-11-21 |
ファイザー・インク |
Cd3に特異的な抗体及びその使用
|
EP3574915A1
(de)
|
2018-05-29 |
2019-12-04 |
Neovacs |
Immunogenes produkt mit il-4 und/oder il-13 zur behandlung von erkrankungen im zusammenhang mit aberranter il-4- und/oder il-13-expression oder -aktivität
|
CN110004150B
(zh)
*
|
2018-08-01 |
2023-03-10 |
中国农业科学院兰州兽医研究所 |
一种具有免疫增强活性的CpG寡聚核苷酸序列及其应用
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
CN113454100A
(zh)
|
2018-12-04 |
2021-09-28 |
洛克菲勒大学 |
Hiv疫苗免疫原
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
US20220023413A1
(en)
|
2018-12-12 |
2022-01-27 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
|
WO2020123989A1
(en)
|
2018-12-14 |
2020-06-18 |
University Of Georgia Research Foundation, Inc. |
Crimean-congo hemorrhagic fever virus replicon particles and use thereof
|
US11642406B2
(en)
|
2018-12-19 |
2023-05-09 |
Merck Sharp & Dohme Llc |
Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
WO2020128893A1
(en)
|
2018-12-21 |
2020-06-25 |
Pfizer Inc. |
Combination treatments of cancer comprising a tlr agonist
|
CN114957407A
(zh)
|
2019-04-02 |
2022-08-30 |
赛诺菲 |
抗原性多聚呼吸道合胞病毒多肽
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
EP3966331A4
(de)
*
|
2019-05-10 |
2023-07-05 |
Microbio (Shanghai) Co., Ltd. |
Dimere cpg-oligonukleotide zur verwendung bei der modulation von immunantworten
|
EP3982983A4
(de)
*
|
2019-06-14 |
2023-11-15 |
G Tech Bio LLC |
Aktivierte lymphozyten und verfahren zu ihrer verwendung zur behandlung von krebs und infektionskrankheiten
|
WO2021015987A1
(en)
|
2019-07-19 |
2021-01-28 |
Merck Sharp & Dohme Corp. |
Antigenic glycoprotein e polypeptides, compositions, and methods of use thereof
|
KR20220041142A
(ko)
|
2019-07-30 |
2022-03-31 |
피브로 애니멀 헬스 코포레이션 |
조류에 점막 투여하기 위한 조성물
|
AU2020323498A1
(en)
|
2019-07-31 |
2022-03-03 |
Sk Bioscience Co., Ltd. |
Multivalent pneumococcal polysaccharide-protein conjugate compositions and methods of using the same
|
WO2021042022A1
(en)
|
2019-08-30 |
2021-03-04 |
University Of Rochester |
Septin inhibitors for treatment of cancers
|
CN110646557A
(zh)
*
|
2019-10-12 |
2020-01-03 |
北京航空航天大学 |
携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
|
AU2020375214B2
(en)
|
2019-11-01 |
2024-02-08 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
EP4077387A1
(de)
|
2019-12-17 |
2022-10-26 |
Pfizer Inc. |
Antikörper mit spezifität für cd47, pd-l1 und verwendungen davon
|
US20230039456A1
(en)
|
2019-12-17 |
2023-02-09 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Live attenuated leishmania parasite vaccines with enhanced safety characteristics
|
US20230241196A1
(en)
|
2020-01-27 |
2023-08-03 |
Oregon State University |
Gonorrhea subunit vaccine
|
BR112022015994A2
(pt)
|
2020-02-13 |
2022-10-11 |
Univ Illinois |
Composição imunogênica multivalente, vetor recombinante, célula hospedeira recombinante, e, métodos para induzir uma resposta imune protetora e para imunizar um animal contra dirofilariose
|
CN115605498A
(zh)
|
2020-02-23 |
2023-01-13 |
辉瑞公司(Us) |
大肠杆菌组合物及其方法
|
JP2023515829A
(ja)
|
2020-02-28 |
2023-04-14 |
サノフィ パスツール インコーポレイテッド |
小児対象のための高用量インフルエンザワクチン
|
US11213482B1
(en)
|
2020-03-05 |
2022-01-04 |
University of Pittsburgh—Of the Commonwealth System of Higher Educat |
SARS-CoV-2 subunit vaccine and microneedle array delivery system
|
WO2021211279A1
(en)
|
2020-04-17 |
2021-10-21 |
Regents Of The University Of Minnesota |
SARS-CoV-2 SPIKE RECEPTOR BINDING DOMAIN AND COMPOSITIONS AND METHODS THEREOF
|
EP3900739A1
(de)
|
2020-04-21 |
2021-10-27 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetische streptococcus-pneumoniae-saccharid-konjugate zum konservierten membranprotein
|
EP4149440A1
(de)
|
2020-05-11 |
2023-03-22 |
Erytech Pharma |
Erythrozyten-extrazellularvesikel (rbevs) mit frachten sowie verfahren zur verwendung und herstellung davon
|
PE20231565A1
(es)
|
2020-07-17 |
2023-10-04 |
Pfizer |
Anticuerpos terapeuticos y sus usos
|
EP4203995A1
(de)
|
2020-08-26 |
2023-07-05 |
Pfizer Inc. |
Gruppe-b-streptococcus-polysaccharid-protein-konjugate, verfahren zur herstellung von konjugaten, immunogene zusammensetzungen mit konjugaten und verwendungen davon
|
WO2022058571A1
(en)
|
2020-09-17 |
2022-03-24 |
Neovacs |
IMMUNOGENIC PRODUCT COMPRISING AN IgE FRAGMENT FOR TREATING IgE-MEDIATED INFLAMMATORY DISORDERS
|
WO2022066965A2
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting sox2 antigens
|
WO2022066973A1
(en)
|
2020-09-24 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Immunotherapy targeting pbk or oip5 antigens
|
KR20230096033A
(ko)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
MX2023005221A
(es)
|
2020-11-04 |
2023-05-16 |
Pfizer |
Composiciones inmunogenicas para uso en vacunas neumococicas.
|
JP2023549736A
(ja)
|
2020-11-10 |
2023-11-29 |
ファイザー・インク |
コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(en)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
|
WO2022169835A1
(en)
|
2021-02-03 |
2022-08-11 |
The Board Of Trustees Of The University Of Illinois |
Vaccine and methods for preventing filariasis and dirofilariasis
|
CA3221075A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022249106A2
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2022261251A1
(en)
|
2021-06-08 |
2022-12-15 |
Glyde Bio Inc. |
Immunogenic compositions comprising tumour-associated antigen
|
EP4104830A1
(de)
|
2021-06-16 |
2022-12-21 |
Burghardt Wittig |
Sequentielle angeborene und adaptive immunmodulation zur krebsbehandlung
|
AU2022311955A1
(en)
|
2021-07-16 |
2024-01-18 |
The Board Of Trustees Of The University Of Illinois |
Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
|
WO2023018817A1
(en)
|
2021-08-11 |
2023-02-16 |
Sanofi Pasteur Inc. |
Truncated influenza neuraminidase and methods of using the same
|
TW202333778A
(zh)
|
2021-10-08 |
2023-09-01 |
美商賽諾菲巴斯德公司 |
多價流感疫苗
|
US20230302112A1
(en)
|
2021-11-05 |
2023-09-28 |
Sanofi |
Respiratory synctial virus rna vaccine
|
WO2023081798A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
|
WO2023079113A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
WO2023102373A1
(en)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Human metapneumovirus vaccines
|
WO2023102388A1
(en)
|
2021-11-30 |
2023-06-08 |
Sanofi Pasteur Inc. |
Human metapneumovirus viral vector-based vaccines
|
WO2023111262A1
(en)
|
2021-12-17 |
2023-06-22 |
Sanofi |
Lyme disease rna vaccine
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023177577A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
WO2023201109A1
(en)
|
2022-04-15 |
2023-10-19 |
Yale University |
Exatecan formulation
|
WO2023214082A2
(en)
|
2022-05-06 |
2023-11-09 |
Sanofi |
Signal sequences for nucleic acid vaccines
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
WO2024003239A1
(en)
|
2022-06-29 |
2024-01-04 |
Bavarian Nordic A/S |
RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
|
WO2024069420A2
(en)
|
2022-09-29 |
2024-04-04 |
Pfizer Inc. |
Immunogenic compositions comprising an rsv f protein trimer
|